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ABSTRACT OF DISSERTATION 
 
 
 
 
A NOVEL LINK BETWEEN ABL FAMILY KINASES AND NM23-H1 
DURING METASTATIC PROGRESSION 
 
Cancer patient mortality is caused by the ability of tumor cells to invade the 
extracellular matrix and metastasize. Our lab was the first to identify the role of Abl 
family of non-receptor tyrosine kinases (c-Abl and Arg) in the progression of solid tumor 
cancers. In our previous studies, we showed that high c-Abl/Arg activity promotes 
proliferation, invasion, and metastasis in melanoma and breast cancer cells lines. Here, 
we demonstrate that our previous findings are clinically relevant by showing increased c-
Abl/Arg kinase activity in primary melanoma tumor tissue in comparison to low activity as 
compared to benign nevi. Additionally, in breast cancer tissue, we found aggressive 
tumor subtypes (triple-negative and high-grade breast cancer) had increased c-Abl/Arg 
activity as compared to less aggressive subtypes. To define the mechanism by which c-
Abl and Arg promote melanoma and breast cancer metastasis, we searched for novel 
pathways by which c-Abl and Arg promote invasion, a key step in metastasis. 
Significantly, we found that c-Abl and Arg decrease the expression of non-metastatic 
protein, NM23-H1, a metastasis suppressor that is lost during metastatic progression. 
We demonstrate that NM23-H1 is localized and degraded within the lysosome via 
proteases, cathepsins L and B. Moreover, we show that c-Abl and Arg upregulate 
cathepsin mRNA levels and activate the cathepsins, which in-turn degrade NM23-H1. 
We demonstrate that this pathway is functionally significant as c-Abl and Arg require the 
downregulation of NM23-H1 to promote invasion in melanoma and breast cancer cell 
lines. We show that the pathway is clinically significant as c-Abl/Arg activity is inversely 
correlated with NM23-H1 expression in mouse lung metastases, as well as in human 
primary melanoma and primary breast cancer tissue. In summary, we are the first to 
demonstrate novel crosstalk between oncogenic and metastasis suppressor signaling 
pathways, and provide evidence that pharmacological inhibition of Abl family kinases in 
melanoma and breast cancer patients may prevent metastatic progression by stabilizing 
a metastasis suppressor. 
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Chapter 1: Introduction 
Melanoma 
Risk Factors, Molecular Mechanisms, and Subtyping 
Melanoma accounts for only 4% of all skin cancers; however, it is responsible for 
80% of skin cancer deaths [1]. The risk factors for melanoma include family history, 
presence of atypical nevi, skin pigmentation patterns, and ultraviolet light exposure [1, 
2]. Nevi (common moles) form from abnormal proliferation of melanocytes in the 
epidermis [1]. Further aberrant proliferation within a nevus or, more commonly, a new 
location of melanocytes forms a lesion that presents histologically with asymmetry, 
irregular coloration, and increasing size [1]. Progression to the radial growth phase is 
characterized by melanocyte invasion into the epidermal skin layer [1], followed by 
progression to the vertical growth phase marked by dermal skin layer invasion allowing 
for metastatic spread to other organs (Figure 1.1) [1].  
Initiation of aberrant proliferation of normal melanocytes is most commonly, albeit 
not exclusively, through activation of the mitogen-activated protein kinase (MAPK) 
pathway via two mutually exclusive activators: the mutated form of the serine/threonine 
protein kinase BRAF or the small GTPase NRAS (Figure 1.1) [1, 3]. Mutated BRAF 
(V600E) or NRAS (Q61K/R) alone in a nevus cannot stimulate progression to a 
malignant phenotype [3]. In fact, forced expression of these oncogenes results in 
senescence within the nevi, thus an additional “hit” is required for melanoma progression 
[4]. Additional mutations promoting melanoma include activation of the PI3K-AKT 
pathway due to the loss of the Phosphatase and Tensin Homolog (PTEN) protein and 
activation of the WNT/β-catenin pathway promoting survival, cell proliferation, spreading 
and migration. Other mutations include hypermethylation, deletion, or mutation of cyclin-
dependent kinase inhibitor 2A (CDKN2A), amplification of the Cyclin D1 (CCND1) locus 
[5, 6], or activation of the receptor tyrosine kinase, cKIT [1]. It is apparent that melanoma 
pathogenesis yields a complex signaling profile, therefore several melanoma subtypes 
have been identified.  
Melanoma cases can be grouped into subtypes based on lesion location and 
sun-exposure. Minimal sun-exposed acral melanomas (palms of hands and soles of 
feet), sun protected mucosal melanomas, and chronic sun-exposed (face) melanomas 
have the largest number of genomic instabilities, which cause mutations within the
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Figure 1.1 Biological and Molecular Events in the Initiation and Progression of 
Melanoma 
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Figure 1.1 Biological and Molecular Events in the Initiation and Progression of 
Melanoma. A benign nevus (common mole) or a new location of melanocytes can 
undergo uncontrolled growth. This is most commonly due to a BRAF or NRAS mutations 
activating the mitogen-activated protein kinase (MAPK) pathway. Radial growth phase 
(RGP) lesions often have loss of PTEN, CCND1 amplification, cKIT mutation and are 
marked by melanocyte invasion into the epidermal layer. Invasion into the dermis marks 
the vertical growth phase (VGP). Figure adapted from: Bertolotto, C. (2013). Scientifica 
(Cairo).  
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CDKN2A/ CCND1 locus paired with amplification of cKIT (Figure1.2) [2, 7]. In contrast, 
intermittent sun-exposed melanomas (trunk, arms, legs) carry a high incidence of BRAF 
or NRAS activating mutations [7].  During chronic sun-exposure, UV radiation leads to 
Melanocortin 1 Receptor (MC1R) activation causing the subsequent activation of 
Microphthalmia Transcription Factor (MITF) which promotes a UV-protective, darkened 
skin pigment [7].  
The term “melanoma” blankets several disease subtypes with unique complex 
signaling pathways. Due to the mutually exclusive nature of these pathways, several 
therapeutic regimens have been designed to combat the disease.  
Current Therapeutics  
 With the discovery that 50% of melanoma patients have the activating BRAF 
mutation, clinical trials were conducted using vemurafenib, a BRAF inhibitor, and 
trametinib, a MEK inhibitor to target the downstream MAPK pathway [8]. Treatment with 
vemurafenib increased median patient survival from 5.7 months to 13.2 months, and 
trametinib gave a median progression free survival at 4.8 months compared to 1.5 
months on a chemotherapy arm [8]. Although these inhibitors showed great promise, 
some tumors harbor intrinsic resistance or acquire resistance over time [8] due to the 
upregulation of compensatory survival pathways such as: reactivation of MEK via NRAS 
or CRAF upregulation, ERK mutations, Cyclin D1 amplification, PI3K/AKT signaling, 
PTEN mutations, PDGFβ overexpression, or IGF1R upregulation [7, 9, 10]. Due to the 
reactivation of MEK signaling in resistant tumors, clinical trials testing combination 
therapies of BRAF and MEK inhibitors are showing promise by inhibiting tumor 
progression and thus increasing survival [7]. However, as previously mentioned, only 
50% of patients have the activating BRAF mutation, therefore other targetable therapies 
are necessary for the treatment of melanoma patients. 
Tumors without mutant BRAF commonly have mutated NRAS. Unfortunately, 
treatment with this mutation has proven to be difficult as NRAS mutations upregulate 
other molecular pathways [8]. Mutated NRAS activates the MAPK pathway via the 
serine/threonine kinase CRAF. Sorafenib, an inhibitor of CRAF as well as BRAF, cKIT, 
and PDGFR, has shown promise by inducing apoptosis in melanoma cell lines [8]. 
Therefore, clinically targeting CRAF could prove to be beneficial in patients with NRAS 
mutations or those that have become resistant to BRAF inhibition [9]. Acral and mucosal 
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Figure 1.2 Genetic mutations in melanoma subtypes.  Melanoma cases can be 
grouped into subtypes based on lesion location and sun exposure. Minimal sun-exposed 
acral melanomas (palms of hands and soles of feet), sun- protected mucosal 
melanomas, and chronic sun-exposed (face) melanomas have the largest number of 
genomic instabilities affecting the CDKN2A/ CCND1 locus paired with amplification of 
cKIT. In contrast, intermittent sun-exposed melanomas (trunk, arms, legs) carry a high 
incidence of activating mutations of BRAF and NRAS. Figure adapted from: Palmieri, G., 
et al. (2013). Melanoma - From Early Detection to Treatment, InTech. 
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melanomas harbor cKIT activating mutations, which are exclusive from, albeit more rare, 
than BRAF and NRAS mutations [7, 9]. A clinical trial using the multitarget inhibitor , 
imatinib mesylate (Gleevec, STI571; targets cKIT, c-Abl/Arg, and platelet derived growth 
factor (PDGFR)) in patients not selected for cKIT mutations resulted in a minimal 
response rate  [11].  The response rate observed in phase II trials selecting for patients 
with cKIT activating mutations showed more promise [12, 13]; however, patients treated 
with this inhibitor often progress due to resistance induced by secondary cKIT mutations 
[3].  
It is clear that melanoma classification is critical for choosing the proper signaling 
pathway to target therapeutically. However, even with proper subtyping, patient 
treatment options are partially successful at best, and the 5-year survival rate for 
patients with metastatic melanoma remains at 14% [14]. This statistic boasts the need 
for additional identification of compensatory mechanisms upregulated with drug 
resistance to provide a more well-rounded treatment option to melanoma patients.  
Breast Cancer 
Molecular Mechanisms, Progression and Clinical Grade 
Similar to melanoma, metastatic, aggressive breast cancer is also difficult to 
treat. With breast cancer being the most common type of cancer among women [15], 
several diagnostic techniques are used to identify treatment options patients. Non-
invasive breast cancer, ductal carcinoma in situ (DCIS), can develop invasive properties 
after acquiring genetic and epigenetic alterations [16]. Using immunohistological 
techniques, invasive carcinoma has been subtyped into estrogen receptor 
(ER)/progesterone receptor (PR) positive (60% of breast cancers), human epidermal 
growth factor 2 (HER2) positive (20% of breast cancers), or triple-negative (lacking 
ER/PR expression and HER2 amplification, 20% of all breast cancers) [15]. The 
combinations of the presence/absence of these markers give five possible molecular 
classifications (Figure 1.3a). ER+/PR+ breast cancers can be subtyped into Luminal A, 
lacking HER2 expression, or Luminal B having HER2 enrichment. ER-/PR- cancers can 
be HER2+ or triple-negative, lacking all three receptors. Triple-negative breast cancers 
can be further divided into basal-like or claudin-low breast cancers, although not all 
basal-like cancers are triple-negative. Both basal-like and claudin-low classifications are 
aggressive with basal-like being highly proliferative and claudin-low exhibiting markers of 
epithelial to mesenchymal transition (EMT) [16, 17]. Finally, tumors classified as normal 
 6 
 
Figure 1.3  Invasive Ductal Carcinoma Classifications and Grade  
Grade I Grade II Grade III 
a
b
 
Figure 1.3 Invasive ductal carcinoma classifications and grade. a) Invasive 
carcinoma is been subtyped into estrogen receptor (ER)/progesterone receptor (PR) 
positive (60% of breast cancers), human epidermal growth factor 2 (HER2) positive 
(20% of breast cancers), or triple-negative (lacking ER/PR expression and HER2 
amplification, 20% of all breast cancers). The combinations of the presence/absence of 
these markers give five possible molecular classifications. ER+/PR+ breast cancers can 
be subtyped into Luminal A, lacking HER2 expression, or Luminal B having HER2 
enrichment. ER-/PR- cancers can be HER2+ or triple negative, lacking HER2. Triple-
negative breast cancers can be further divided into basal-like or claudin-low breast 
cancers. Both basal-like and claudin-low classifications are aggressive with basal-like 
being highly proliferative and claudin-low exhibiting markers of epithelial to 
mesenchymal transition (EMT).  Adapted from Sandhu et al. (2010) LabMedicine, 41, 
364-372. b) Grade I is a well differentiated tumor with normal breast tissue homology, 
mild nuclear pleomorphism, and low mitotic count. Grade II is moderately differentiated 
and grade III is poorly differentiated with high pleomorphism, frequent mitosis, and lack 
of tubule formation. Figure adapted from Rakha et al. Breast Cancer Research 2010, 
12:207 .
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breast-like resemble normal breast tissue and can be characterized molecularly due to 
high expression of non-epithelial markers, however a distinct molecular profile has yet to 
be defined [18]. Normal breast-like tumors have a good prognosis [18].  
Histological tumor grade is a clinical prognostic tool used to evaluate tumor 
morphological features such as tubule/gland formation, nuclear pleomorphism, and 
mitotic count [19]. Grade I is a well differentiated tumor with normal breast tissue 
homology, mild nuclear pleomorphism, and low mitotic count. Grade II is moderately 
differentiated and Grade III is poorly differentiated with high pleomorphism, frequent 
mitosis, and no tubule formation (Figure 1.3b) [19]. Increasing grade has been linked 
with decreased survival and it has been suggested that tumor grade predicts tumor 
behavior accurately, even more so than tumor size [19, 20]. In addition to grade, TNM 
tumor staging is used clinically to assess progression. The “T” (0-4) describes tumor 
size, the “N” (0-3) indicates lymph node spreading, and “M” (0 or 1) indicates metastatic 
spread [21]. One of five stages can be assigned to a tumor: Stage 0 (non-invasive), 
Stage I (invasive, less than 2cm), Stage II (spread to lymph nodes), Stage III (spread to 
lymph nodes near the breast bone), Stage IV (metastatic spread to distant organs) [22].  
 Current treatments for patients with early stage breast cancer yield positive 
outcomes; however, 33% of patients with early stage breast cancer will develop 
metastases. Metastatic breast cancer remains incurable with a five-year survival rate of 
only 23% [15] indicating the need for further investigation of the molecular mechanisms 
causing metastasis and decreased mortality in breast cancer patients.  
Current Therapeutics 
As previously mentioned, immunohistological examination of breast tumors 
allows for targeted therapy for the patient. ER+/PR+ tumor patients have a favorable 
prognosis (80-85% 5 year survival rate) [16] due to the availability of targeted treatment 
using an estrogen receptor antagonist such as Tamoxifen or estrogen lowering 
aromatase inhibitors such as Letrozole. Similarly, some patients with HER2+ tumors also 
may have a favorable outcome due to targetable therapy against the HER2 receptor 
using the HER2 monoclonal antibody, Trastuzumab, or inhibition of HER2 downstream 
signaling via Lapatinib [15]. Unfortunately, many of these HER2+ tumors  (70%) show 
drug resistance against Trastuzumab, therefore other therapeutic options are currently in 
clinical trials such as Trastuzumab-DMI, a combination of the monoclonal antibody with 
a fungal toxin for targeted drug delivery of Trastuzumab to HER2 overexpressing cells 
[15].  
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 Unlike ER+/PR+ and HER2+ tumors, triple-negative tumors are more difficult to 
treat due to lack of therapeutic targets [17]. Therefore the most common treatments are 
cytotoxic agents including anthracyclines (topoisomerase II inhibition) such as 
doxorubicin or taxanes (mitotic spindle inhibition) such as paclitaxel [17]. Inhibition of 
poly ADP-ribose polymerase (PARP), vascular endothelial growth factor (VEGF), and 
PI3K/AKT are a few of the current molecular targets being investigated. The need for 
molecular targets for triple-negative breast cancer is urgent to provide more rational 
treatment options for patients [17].  
Vesicular Trafficking 
Endosome to Lysosome Maturation and Function 
Once thought to be simple vesicles utilized for protein transport, we now know 
that vesicular trafficking and endosomes play a role in several cancer functions such as 
receptor tyrosine kinase regulation, cytokinesis, and migration [23, 24]. Cargo proteins 
from the endoplasmic reticulum (ER) are delivered to early endosomes from the trans-
golgi network (TGN) or from the plasma membrane via endocytosis (Figure1.4) [25]. 
Once in the early endosome, proteins are either trafficked back to the plasma membrane 
via recycling endosomes or are ubiquitin-tagged for degradation [25]. Ubiquitinated 
proteins are sorted into endosomal membrane invaginations known as intraluminal 
vesicles (ILVs) via a process mediated by Endosomal Sorting Complex Required for 
Transport (ESCRT) proteins. However, ESCRT-independent ILV sorting for non-
ubiquitinated cargo exists for a subset of ILVs (melanosomes and exosomes) [26].  The 
ILV-filled endosome, known as a multi-vesicular body, is considered a hybrid between 
the early and late endosomes [23, 25].  Further endosomal maturation forms the 
endolysosome (a hybrid vesicle prior to full lysosome maturation) [23].   
Just as the endosome has been debunked as a simplistic organelle, the 
lysosome can no longer be thought of as simply the trashcan at the end of the endocytic 
pathway. The lysosome is best known for its role in the degradation of cellular 
components via 50 different hydrolases (proteases, phosphatases, nucleases, etc.) [27, 
28]. However, it has also been shown to have roles in cholesterol homeostasis, plasma 
membrane repair, cell death, and cell signaling [27]. Proteins destined for degradation 
can be delivered to the lysosome via protein chaperones, autophagosomes, or
 9 
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Figure 1.4 Endosomal/Lysosomal vesicular trafficking.  a) Cargo proteins from the 
trans-golgi network (TGN) or b) endocytosed from the plasma membrane are delivered 
to the early endosomes. Once in the early endosome, proteins are either c) trafficked 
back to the plasma membrane via a recycling endosome or ubiquitin tagged for 
degradation. d) Ubiquitinated proteins are sorted into endosomal membrane 
invaginations known as intraluminal vesicles (ILVs). The ILV filled endosome, known as 
a multi-vesicular body, is considered a hybrid between the early and late endosomes. e) 
Continued endosomal maturation forms the endolysosome (a hybrid vesicle prior to full 
lysosome maturation) which matures into the lysosome. Figure adapted from Huotary et 
al. EMBO J. 2011 Aug 31;30(17):3481-500. 
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endosomes [29] and cleaved via cathepsin-mediated hydrolysis in a substrate-specific 
manner [28]. During the maturation of endosomes to lysosomes several changes occur: 
acquisition and loss of membrane components, intraluminal acidification, and vesicular 
localization from the cell periphery to the perinuclear region [23].  
 Dynamic vesicular membrane components are necessary for endosome 
maturation and also provide convenient markers for vesicular identification. Rab GTPase 
proteins have an integral role in vesicle docking, fusion, and motility by recruiting effector 
proteins via activation by a guanine exchange factor (GEF) [30]. The Rab GTPase is 
delivered to the vesicle membrane via a GDP dissociation inhibitor (GDI). GEFs convert 
the Rab-GDP state to GTP, which can then recruit and bind an effector (Figure1.5a). At 
the early endosome, recruitment and activation of the Rab5 GTPase, via the Rabex5 
GEF promotes the recruitment of the Rab5 effector protein phosphoinositide 3-kinase 
(PI3K) generating phosphatidylinositol 3-phosphate (PI3P) lipid accumulation 
(Figure1.5b) [30]. This accumulation recruits the late endosome-specific GEF, 
Mon1/Ccz1. Mon1/Ccz1 then recruits the late endosome specific Rab7 GTPase [30]. 
Mon1/ Ccz1 has been shown to displace Rabex5, yielding a Rab5/Rab7 switch [30, 31]. 
Further maturation involves the acquisition of over 25 known lysosomal membrane 
proteins, the most abundant being LAMP1 and LAMP2 [27, 32, 33] resulting in 
lysosomal localization to the perinuclear region and fusion with other vesicles [33, 34].  
In addition to the presence of essential membrane proteins, endosome/lysosome 
functionality is dependent upon intraluminal acidification [35]. As the endosome matures 
into a lysosome the pH decreases from ~6.8 to ~4.5 [35]. Acidification is achieved via 
large trans-membrane protein pumps, V-ATPases, which promote protease activation, 
routing of sorted cargo, and membrane trafficking [23]. Unprotonated lysosomotropic 
weak bases (ammonium chloride, chloroquine) act as lysosome inhibitors by binding free 
protons thus increasing the pH.  Another inhibitor, bafilomycin A, increases pH via direct 
ATPase inhibition. Interestingly, bafilomycin A blocks maturation of late endosomes to 
lysosomes whereas the lysosomotropic weak bases do not, suggesting that in addition 
to pH changes, these inhibitors have other effects [23]. 
As early endosomes mature, they migrate from the cell periphery towards the 
perinuclear region [23]. Endosome movement along microtubules is regulated by kinesin 
and dynein motor proteins. This endosomal movement is necessary for the Rab5/Rab7 
switch and cargo delivery for lysosomal degradation [23]. In addition to microtubules 
promoting endosomal movement, localization of the actin nucleation promoting factor,
 11 
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Figure 1.5 Endosomal membrane protein recruitment. Rab GTPase proteins have an 
integral role in vesicle docking, fusion, and motility by recruiting effector proteins via 
activation of a guanine exchange factor (GEF). a) The Rab GTPase is delivered to the 
vesicle membrane via a GDP dissociation inhibitor (GDI). GEFs convert the GDP to GTP 
which can then recruit and bind to an effector. b) Rab5 GTPase is recruited to the early 
endosome via the Rab5 GEF, Rabex 5. Rab5 promotes the recruitment of the Rab5 
effector protein phosphoinositide 3-kinase (PI3K) generating phosphatidylinositol 3-
phosphate (PI3P) lipid accumulation. This accumulation recruits Mon1/Ccz1 (a late 
endosome specific GEF). Mon1/Ccz1 then recruits the late endosome specific Rab7 
GTPase. Mon1/ Ccz1 has been shown to displace Rabex5 and Rab5 GTPase, an action 
known as the Rab5/Rab7 switch. Figure adapted from: Pfeffer et al. Curr Opin Cell Biol. 
2013 Aug;25(4):414-9. 
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WASH, to the endosomal membrane promotes endosomal trafficking and sorting via 
activation of the actin nucleation complex, ARP2/3 [36]. 
Perinuclear localization, membrane component switching, and acidification are all 
necessary for the delivery of proteins destined for degradation to the lysosome. 
Additionally, proper delivery and activation of cathepsin proteases is essential for 
lysosomal protein degradation and function. 
Cathepsin Activation and Function 
 Within the lysosome, cathepsin proteases are primarily responsible for protein 
degradation. There are currently 15 cathepsins classified based on the active site 
residues: 11 cysteine, 2 serine and 2 aspartic proteases [37]. Most cathepsins are 
synthesized as preproenzymes with “pre” referring to the N-terminal signal targeting the 
cathepsin to the Endoplasmic Reticulum (Figure 1.6a) [37], however alternative splicing 
can produce cathepsins lacking the signal peptide, targeting these cathepsins to areas 
other than the ER such as the nucleus or mitochondria [38].  The “pro” refers to the N-
terminal propeptide which assists in proper protein folding and additionally acts as an 
inhibitor covering the enzyme active site [37]. Cathepsin inhibition is necessary to 
prevent damage to cellular components prior to the cathepsin being localized to a 
vesicle [37]. The “pre” signaling peptide is cleaved in the ER and the glycosylated 
cathepsin is trafficked to the golgi apparatus where it undergoes mannose-6-phosphate 
(M6P) modification promoting mannose-6-phosphate receptor (M6PR) binding 
(Figure1.6b). Binding to the M6PR results in sorting of the cathepsins to the early 
endosomes and late endosomes [38]. The low pH within the early endosomes induces 
cathepsin release from the M6PR and the active site is exposed via protein unfolding  
[39]. Once localized within the late endosome, the cathepsin propeptide is cleaved due 
to an increase in acidity, producing an active single-chain form of the cathepsin (Figure 
1.6c) [38]. Trafficking of the single-chain active cathepsin to the even more acidic 
lysosome induces an additional cleavage producing the double-chain active form of the 
cathepsin (Figure 1.6d) [38].  
Cathepsins have a variety of functions in addition to lysosomal protein turnover 
including antigen presentation (cathepsin S), cell cycle regulation (cathepsin L), bone 
remodeling (cathepsin K), reproduction (cathepsin V), hormone activation (cathepsin V) 
and cancer progression (cathepsin L, B, D) [37, 40]. Cathepsins L and B are commonly 
upregulated in melanoma and breast cancer, and promote tumor progression, invasion 
and metastasis [37, 41]. Increased expression of these cathepsins is accompanied by 
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Figure 1.6 Cathepsin activation via endosomal trafficking. a) Within the endoplasmic 
reticulum, the cathepsin N-terminus signaling peptide is cleaved and the cathepsin is 
glycosylated then trafficked to b) the golgi apparatus where it undergoes mannose-6-
phosphate modification inducing binding of the cathepsin to the mannose-6-phosphate 
receptor (M6PR). Binding to the receptor sorts the cathepsin to the early and late 
endosomes. c) Decreased pH within the early endosomes induces cathepsin release 
from the M6PR and unfolding of the protein exposing the active site. Once in the late 
endosome, the inhibitory propeptide is cleaved producing the active single-chain form of 
the cathepsin. d) Trafficking of the single-chain active cathepsin to the lysosome, which 
is even more acidic, induces additional cleavage producing the double-chain active form 
of the cathepsin. e) In cancer cells, increased expression of cathepsins is accompanied 
by decreased affinity for the M6PR within the golgi , which prevents cathepsin targeting 
to the endosomes subsequently causing the procathepsin to be trafficked to the plasma 
membrane and secreted into the extracellular environment. Figure adapted from: Reiser, 
et al. J Clin Invest. Oct 1, 2010; 120(10): 3421–3431. 
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decreased affinity for the M6PR within the golgi preventing cathepsin targeting to the 
endosomes [39]. The excess procathepsins within the golgi are then trafficked to 
theplasma membrane and secreted into the extracellular environment [37].  Once 
secreted, the acidic extracellular tumor environment promotes cathepsin activation [39]. 
Several mechanisms have been reported for extracellular cathepsins to promote 
invasion and metastasis. First, they directly cleave and degrade the basement 
membrane and extracellular matrix components such as type IV collagen, laminin and 
fibronectin [37]. Second, they can activate other proteases involved in ECM degradation 
such as the matrix metalloproteinases (MMP-1 and MMP-3) [40] and the urokinase 
plasminogen activator system [37]. Finally, they cleave and inactivate cell adhesion 
proteins such as E-cadherin, which promotes a more invasive migratory phenotype [40].  
Intracellular cathepsins have also been reported to affect tumorigenicity, although they 
have been reported to both promote and prevent tumor progression. Intracellular 
cathepsins can promote tumorigenesis by degrading collagen which is endocytosed [37]. 
Conversely, they can inhibit tumorigenesis by degrading the anti-apoptotic protein Bcl-2, 
thus activating mitochondrial-induced apoptosis [37]. Data demonstrating specific 
intracellular substrates for cathepsins L and B are scarce, and it is generally accepted 
that cathepsin overexpression within these tumors promotes an invasive, metastatic 
phenotype. Therefore, undiscovered intracellular functions of cathepsins may exist 
promoting breast cancer and melanoma.  
Abl Family Kinases  
Structure and Regulation 
  Oncogenes are proteins that drive the progression of cancer. The oncogenes c-
Abl and Arg (Abl Related Gene) comprise the Abl family of non-receptor tyrosine 
kinases. These kinases are highly conserved in the amino-terminal region, which 
contains an SH3, SH2, and kinase domain (Figure 1.7a) [42]. The c-Abl and Arg genes, 
ABL1 and ABL2, generate two isoforms, 1a and 1b, with distinct N-terminal sequences 
due to alternative splicing of the first exons [43]. Isoform 1b contains a myristolation site 
at the N-terminus, which targets the kinases to the plasma membrane, whereas the 1a 
isoform originates from an alternative promoter yielding a truncated N-terminus, which 
lacks the myristolation site [44]. Although both kinases contain F-actin binding domains 
in the carboxyl terminus, c-Abl and Arg are less conserved in the C-terminus.  Arg 
contains an additional F-actin domain and lacks the nuclear localization signals (NLS) 
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Figure 1.7 Abl Family Kinase Structure and Activation  
 
Figure 1.7 Abl family kinase structure and activation. a) c-Abl and Arg kinases are 
highly conserved in the amino-terminal region, which contains an SH3, SH2, and kinase 
domain. The c-Abl and Arg genes, ABL1 and ABL2, generate two isoforms, 1a and 1b, 
with distinct N-terminal sequences due to alternative splicing of the first exons. Isoform 
1b contains a myristolation site at the N-terminus, which targets the kinases to the 
plasma membrane, whereas the 1a isoform originates from an alternative promotor 
yielding a truncated N-terminus, omitting the myristolation site. In the carboxyl terminus, 
Arg contains an additional F-actin domain and lacks the nuclear localization signals 
(NLS) and nuclear export signals (NES) present in c-Abl. b) Intramolecular inhibition of 
the Abl family kinases occurs when the SH3 domain interacts with the linker region 
between the SH2 and kinase domains or the myristolation residue binds the C-lobe 
within the kinase domain creating a folded conformation. Tyrosine phosphorylation on 
Y412/Y439 (c-Abl/Arg) in the activation loop and Y245/Y272 (c-Abl/Arg) in the SH2 linker 
region unfolds the proteins and stabilizes the active conformation. Imatinib and nilotinib 
are competitive inhibitors of the ATP-binding pocket of the kinase domain, preventing 
ATP from binding, and thus, preventing the transfer of the γ-phosphate from ATP to a 
substrate.  a,b) Figures adapted from Sirvent, et al. Biol Cell. 2008 Nov;100(11):617-31 
c) Figure adapted from http://www.cancer.govnewscenter/newsfromnci/2001/ 
gleevecpressrelease 
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and nuclear export signals (NES) present in c-Abl (Figure 1.7a) [44]. Intramolecular 
inhibition of the Abl family kinases occurs when the SH3 domain interacts with the linker 
region between the SH2 and kinase domains or the myristolation residue binds the C-
lobe within the kinase domain creating a folded conformation (Figure 1.7b) [43, 45].  
Tyrosine phosphorylation on Y412/Y439 (c-Abl/Arg) in the activation loop and 
Y245/Y272 (c-Abl/Arg) in the SH2 linker region unfolds the proteins and stabilizes the 
active conformation [46]. Proteins that have been identified as c-Abl and Arg activators 
are EGFR, PDGFR, PLC-γ, and Src kinases [47, 48]. Endogenous inhibitors of c-Abl/Arg 
include the Abl interactor proteins (Abi-1 and  Abi-2), peroxiredoxin-1 (PRDX-1/PAG1), 
phosphatidyl inositol bisphosphate (PIP2) and the tumor suppressor FUS1; however, 
high expression of c-Abl and Arg, such as following transfection in 293T cells, can titrate 
out the inhibitors leading to constitutive activation [42, 49]. 
c-Abl and Arg  localize to the cytoplasm and plasma membrane. Additionally, due 
to the presence of three NLS and a NES, c-Abl can also translocate to the nucleus in 
response to DNA damage and promote transcription and promote apoptosis [50]. 
Although nuclear c-Abl promotes apoptosis, cytoplasmic c-Abl and Arg have an 
opposing oncogenic, anti-apoptotic role. Furthermore, activation of cytoplasmic c-Abl 
and Arg in fibroblasts promotes cytoskeletal reorganization by phosphorylating N-Wasp, 
WAVE and cortactin allowing these proteins to interact with the Arp2/3 complex 
stimulating actin polymerization [46, 51]. c-Abl and Arg mediate actin polymerization in 
fibroblasts in response to growth factor stimulation which leads to cytoskeletal 
reorganization, membrane ruffling, and lamellipodia formation [46, 47].  
c-Abl has been studied extensively in chronic myelogenous leukemias (CML), 
where a portion of the BCR gene fuses to the c-ABL gene. This fusion causes a deletion 
of the c-Abl gene resulting in a constitutively active BCR-Abl fusion protein which 
promotes the development of leukemia [49]. Imatinib mesylate (Gleevec, STI571) is an 
inhibitor of the Abl family kinases developed for patients with CML [52]. Imatinib 
stabilizes the inactive non-ATP binding form of c-Abl/Arg by binding to the ATP-binding 
pocket of the protein, and thus, prevents the transfer of the γ-phosphate from ATP to a 
substrate (Figure 1.7c) [52]. A second-generation inhibitor, nilotinib, was been developed 
for patients with resistance or adverse side effects to imatinib therapy [53]. Nilotinib 
binds and inhibits the Abl family kinases with greater specificity and potency coupled 
with less toxicity as compared to imatinib [53]. Imatinib and nilotinib also target cKIT and 
PDGFRα/β [52, 53] while nilotinib also inhibits DDR-1/2 and CSF-1R [54]. In addition to 
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nilotinib, other c-Abl/Arg inhibitors such as dasatinib and bosutinib have been developed 
to treat tumors with resistance to imatinib therapy [55]. A T315I mutation within the 
kinase domain of c-Abl/Arg causes a conformational change that induces resistance to 
most c-Abl/Arg inhibitors; however, ponatinib and DCC-2036 are multi-target inhibitors 
that inhibit all mutant forms of c-Abl/Arg, including T315I mutations [55]. 
Role in Solid Tumors 
Our laboratory was the first to observe increased c-Abl and Arg activity in 
invasive breast cancer and melanoma cells as compared to human mammary epithelial 
cells (HMEC) and primary melanocytes [56, 57]. Subsequently, Abl family kinase 
activation has also been reported in glioblastoma, non-small cell lung cancer, gastric 
carcinoma and hepatocarcinomas [58-60]. In solid tumors, Abl family kinases are 
sequestered within the cytoplasm, where deregulated activation via EGFR, HER2, SRC, 
or IGF1R promotes proliferation, anchorage independent growth, invasion and 
metastases [56, 57, 61]. Our lab demonstrated that Abl family kinases promote invasion 
in melanoma cells via upregulation of matrix metalloproteinases (MMP-1, MMP-3, and 
MT1-MMP) and upregulation of MMP-1 occurs via a STAT3 dependent mechanism [57]. 
However, re-expression of these MMPs only partially rescued the decrease in invasion 
observed in c-Abl and Arg knockdown cells [57], indicating that c-Abl and Arg likely 
promote invasion in melanoma and breast cancer cells via multiple mechanisms. The 
success that c-Abl/Arg inhibitors, imatinib and nilotinib, have achieved in CML patients 
has yet to be translated to use in solid tumors cancers due to clinical trials not selecting 
for patients expressing high c-Abl/Arg activity. Regardless of the design pitfalls in the 
solid tumor clinical trials for these drugs, imatinib and nilotinib have proven to be 
invaluable for the investigation of c-Abl and Arg mechanisms in normal and cancer cells. 
Involvement in Protein Turnover 
c-Abl and Arg also have a role in endocytosis and protein turnover. Protein 
turnover within the cell occurs via two common mechanisms: ubiquitin-proteasomal 
degradation or lysosomal degradation. In hematopoietic cells, BCR/Abl promotes the 
proteasomal degradation of the Abi-2 proteins via tyrosine phosphorylation [62]. 
Additionally, c-Abl promotes the proteasomal-mediated degradation of DNA binding 
proteins in a kinase independent manner [63]. In addition to proteasomal degradation, c-
Abl also has a role in vesicular movement and lysosomal degradation. c-Abl promotes B-
cell receptor endocytosis via cytoskeletal remodeling [64] and both c-Abl and Arg were 
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found to promote autophagosome movement and delivery of proteins to the lysosome 
[65]. Conversely, c-Abl and Arg can also prevent the degradation of proteins, as c-
Abl/Arg- mediated tyrosine phosphorylation of EGFR prevents endocytosis, which 
increases its stability and promotes cell surface expression [66]. Furthermore, c-Abl/Arg- 
mediated phosphorylation of galectin-3 prevents lysosomal degradation of galectin-3 
[67]. Thus, it is clear that c-Abl/Arg affect protein turnover, and whether they promote or 
inhibit turnover may depend the cell type, the targeted substrate, and the activation level 
of the Abl family kinases. Therefore, although these reports provide evidence for c-Abl 
and Arg involvement in these processes, there remains much to be discovered about the 
involvement of Abl family kinases in mechanisms of vesicular trafficking and lysosomal 
mediated degradation.  
NM23-H1 
Role and Functions in Cancer 
 Oncogenes drive the progression of cancer; however, proteins such as NM23-H1 
reduce the metastatic capabilities of cancer cells. The human NM23 (NME, NDPK) 
family of proteins currently contains 10 homologs (H1-H10), with NM23-H1 being the 
most studied due to its anti-metastatic role [68]. High NM23-H1 RNA expression was 
first observed in murine melanoma cell lines with low metastatic potential as compared 
to highly metastatic cell lines having low NM23-H1 expression [69]. Transfection of 
NM23 into melanoma cells reduced motility and metastasis with little effect on tumor 
growth, supporting NM23-H1 as a metastasis suppressor rather than a tumor suppressor 
[70-72]. Since this discovery, reduction in NM23-H1 expression has been associated 
with aggressive tumors in gastric carcinoma, ovarian cancer, breast cancer, and 
melanoma tumors [68]. However, interestingly, in some diseases such as 
neuroblastoma, osteosarcoma, and hematological cancers, increased NM23-H1 
expression correlates with poor survival [68]. Three biological functions have been 
identified for NM23-H1: nucleoside diphosphate kinase (NDPK), histidine kinase [68], 
and 3’->5’ exonuclease [73].   
As a nucleoside diphosphate kinase, NM23-H1 has the ability to add the terminal 
phosphate from a nucleotide triphosphate (NTP) onto a nucleotide diphosphate (NDP) 
[74]. Most of the NDPK functions reported for NM23-H1 involve G-protein regulation.  
NM23-H1 binds the Rac1 GEF, TIAM1 [75], and the CDC42 GEF, Dbl-1, which inhibits 
the activation of Rac1 and CDC42, preventing lamellipodia and filopodia formation, and 
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thus promoting an adhesive, less migratory phenotype [76]. Conversely, interaction with 
another GTPase, ARF6, suggests a promigratory role for NM23-H1. ARF6 recruits and 
interacts with NM23-H1, promoting-dynamin dependent endocytosis of E-cadherin, a 
process involved in epithelial to mesenchymal transition (EMT) [77]. However, ARF6 
recruitment of NM23-H1 also inhibited TIAM1, reducing Rac1 activation, which would 
typically promote a more adhesive, less migratory phenotype [77]. It is worth noting that 
these experiments were conducted in polarized, epithelial MDCK cells; therefore NM23-
H1 effects could differ between well-differentiated and less-differentiated cells and also 
could be different in mesenchymal (invasive) vs. epithelial (non-invasive) cancer cells. 
The NDPK function of NM23-H1 is necessary for its histidine kinase function, in which 
NM23-H1 transfers a phosphate from an NTP onto a histidine residue within NM23-H1 
and then subsequently transfers the phosphate to another protein [74]. This histidine 
kinase activity is involved in phosphorylation-induced degradation of the Kinase 
Suppressor of Ras (KSR), which results in ERK pathway inhibition [74]. NM23-H1 also 
interacts with a host of other proteins, including inhibiting the ERα transcription factor 
causing downregulation of ERα specific genes [78]. Furthermore, NM23-H1 expression 
downregulates the GPCR, EDG2, decreasing motility and metastatic lung colonization 
[74]. Finally, NM23-H1 also has DNA-binding functions as it has been identified as a 3’-
>5’ exonuclease [73, 79]. NM23-H1 promotes nucleotide excision repair of UVR-induced 
(6-4) photoproducts [79]. Furthermore, mice with a deficiency in murine nm23-m1 and 
nm23-m2 (HGF+ x [m1m2] +/-) have increased incidence of UVR-induced metastases as 
compared to HGF+ mice [80], demonstrating that the 3’->5’ exonuclease function of 
NM23-H1 is required for metastasis suppression. 
Upstream Regulators of NM23-H1 
The list of NM23-H1 binding partners and potential mechanisms for metastasis 
suppression is extensive; however, less information is available regarding upstream 
regulators of NM23-H1. Phosphorylation of NM23-H1 by casein kinase I (CKI) promotes 
binding of NM23-H1 to the phosphodiesterase (PDE), h-prune, subsequently preventing 
NM23-H1 from suppressing metastasis [81]. This interaction is speculated to promote 
metastasis by h-prune sequestering NM23-H1, thus, preventing its metastatic functions 
or by enhancing the PDE activity of h-prune leading to increased motility [82]. Aurora-A 
kinase has also been demonstrated to phosphorylate NM23-H1, however the functional 
significance of this interaction has yet to be determined [81]. Furthermore, plakoglobin, 
which has tumor suppressive activity via tethering cadherin-catenin complexes to actin, 
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increases NM23-H1 expression by binding and activating the NM23-H1 promoter when 
exogenously expressed [83, 84]. As previously mentioned, NM23-H1 was found to 
regulate the activation of ERα, and interestingly ERα in turn increases NM23-H1 
transcription [85].  
NM23-H1 is a potent metastasis suppressor; therefore, the ability to 
therapeutically increase NM23-H1 expression in patient tumors could decrease 
metastasis leading to increased survival. As such, compounds are being pursued in the 
clinic to decrease metastasis through upregulation of NM23-H1. Several compounds 
have been demonstrated to increase NM23-H1 expression including the glucocorticoid 
receptor (GR) agonists, dexamethasone, prednisolone and medroxyprogesterone 
acetate (MPA) [74].  Of the three GR agonists tested, only MPA increased NM23-H1 
expression in the presence of serum, indicating it would be effective within the 
bloodstream [86]. MPA decreased anchorage-independent colonization and pulmonary 
metastases in vivo [86, 87]; however, increased survival was seen primarily in older 
patients; indicating that MPA treatment is limited to post-menopausal women [74, 86, 
87]. An alternative to drug-induced NM23-H1 expression is delivery of NM23 protein by 
fusion of NM23 to a hydrophobic macromolecule transduction domain (MTD) creating a 
cell-permeable NM23 (CP-NM23) [88]. Delivery of CP-NM23 within metastatic cell lines 
reduced cell migration, invasion, MEK signaling and EDG2 expression (known 
downstream effects of NM23-H1) [88]. Furthermore CP-NM23 inhibited formation of lung 
metastases, cleared existing metastases, and increased survival as compared to MPA-
treated mice [88].  
In summary, these data demonstrate that re-expression of NM23-H1 within 
tumors dramatically reduces metastases and increases overall prognosis. Therefore, 
there is a need to expand upon the information we have regarding the cell signaling 
pathways involved in the regulation of NM23-H1 expression to rationally identify 
compounds that could increase NM23-H1 expression to improve patient survival.  
Project Objectives 
 Our lab previously demonstrated that c-Abl and Arg are highly activated in 
invasive melanoma and breast cancer cells and showed their activation is required for 
proliferation, anchorage independent growth, invasion and metastasis [57, 61]. 
Therefore, we hypothesize that Abl family kinases are highly activated in aggressive 
melanoma and breast cancer primary tissue. To test this hypothesis we will analyze c-
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Abl/Arg activity in primary melanomas as compared to benign nevi, young vs. aged, and 
within sun-exposure subtypes (Chapter 2). Additionally, we will examine whether c-
Abl/Arg activation is increased in high-grade or triple-negative breast cancers (Chapter 
2).   
 We also demonstrated that c-Abl/Arg promote invasion via upregulation and 
activation of MMP1, MMP-3, and MT1-MMP in melanoma cells. However, as we stated 
above, overexpression of these MMPs only partially rescued the decrease in invasion 
observed in c-Abl/Arg knockdown cells [57]. This partial rescue leads us to hypothesize 
that c-Abl/Arg promote invasion via multiple pathways in breast cancer and melanoma. 
Here, we describe an additional mechanism by which c-Abl/Arg promote invasion via 
downregulation of the metastasis suppressor, NM23-H1 (Chapter 3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Leann S. Fiore 2014 
 22 
Chapter 2: Abl Family Kinase Activity and NM23-H1 
Expression in Solid Tumors 
Introduction 
  Previously, our laboratory studied the role of c-Abl and Arg in solid tumor 
progression within melanoma and breast cancer cell lines. Melanoma and invasive 
breast cancer cells had higher c-Abl/Arg kinase activity in comparison to primary 
melanocytes and non-invasive breast cancer cells, respectively [56, 57]. Interestingly, 
protein expression of c-Abl and Arg in these cells did not correlate with their overall 
activity [56, 57]. Furthermore, inhibition of c-Abl and Arg with imatinib mesylate 
attenuated their ability to invade matrigel in vitro, and nilotinib treatment attenuated 
metastatic burden in vivo [56, 57, 89]. These findings demonstrate c-Abl and Arg 
activation promotes melanoma and breast cancer progression, and provide evidence 
that c-Abl/Arg activities cannot be assessed via their expression levels alone. 
Several groups have examined c-Abl expression in primary solid tumors such as 
lung, lymphoma, colon, brain, renal, ovarian, stomach, and melanoma [90-94]. However, 
since c-Abl/Arg kinase activity is essential for c-Abl and Arg driven progression, and 
expression is not an indicator of activity, these studies failed to properly depict the role of 
c-Abl and Arg in these carcinomas. In an attempt to assess c-Abl and Arg kinase activity 
in endometrial cancer tissue, one group used an antibody directed against tyrosine 
phosphorylation sites on c-Abl [95], however, commercially available phospho-Abl 
antibodies cross-react with phospho-EGFR and phospho-PDGFR. Given that phospho-
Abl antibodies lack specificity for c-Abl and Arg, one can’t be certain that the 
investigators were analyzing activity specific to c-Abl/Arg. Although there is no way to 
directly measure c-Abl/Arg activity in tissues, we believe that indirect measurement of 
activity using an antibody directed against c-Abl and Arg tyrosine phosphorylation sites 
on a known c-Abl/Arg substrate such as Crk/CrkL might be a viable alternative method. 
Although other proteins have been shown to phosphorylate Crk/CrkL in vitro, c-Abl/Arg 
double knockout cells had undetectable phosphorylation on Y221 (Crk) and Y207 (CrkL) 
[96], and silencing or inhibiting c-Abl and Arg, in cancer cells, completely inhibits 
Crk/CrkL phosphorylation [56]. Singer, et al. stained several primary tumor types for 
pCrk/CrkL and found staining in brain, ovarian, colon, lymphoma, lung, and of particular 
interest to our studies, melanoma (57% stained positive) and breast cancer (49% 
stained positive) [97]. However, they did not compare the intensity of pCrk/CrkL staining 
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within the subtypes of these cancers. Therefore the need exists for assessment of c-
Abl/Arg kinase activity via pCrk/CrkL staining in melanoma subtypes such as age and 
sun-exposure and breast cancer subtypes such as grade and receptor expression 
(HER2/ER/PR/triple-negative) to determine if c-Abl and Arg activity within a particular 
subtype is associated with an aggressive, metastatic phenotype.  
In contrast to the few studies depicting c-Abl/Arg activity in primary melanomas 
and breast cancers, NM23-H1 expression has been investigated in several primary 
tumor tissues such as ovarian, gastic, melanoma and breast cancer [98, 99]. In 
melanoma, high NM23-H1 mRNA/protein expression has been linked to increased 
survival rates [100], decreased tumor thickness [100-102], decreased invasion [100, 
101] and fewer metastases [102-104]. However, there are also conflicting reports that 
demonstrate high NM23-H1 expression associated with decreased survival [105], 
invasion, and metastases [105, 106]. Additionally, although there is data linking 
increased NM23-H1 expression with increased patient age [105], there is little data 
examining expression of NM23-H1 in various melanoma sun-exposure subtypes. A 
correlation between NM23-H1 expression and sun-exposure subtypes could further 
define the molecular differences in these subtypes and provide evidence for utilizing 
NM23-H1 expression as a prognostic marker for assessing the metastatic potential 
within a patient tumor. 
In breast cancers, high NM23-H1 mRNA and protein levels were observed in 
low-grade tumors lacking lymph node involvement, and NM23-H1 expression was 
associated with increased overall survival [107-112]. To evaluate whether NM23-H1 
could be a potential prognostic marker, other studies compared NM23-H1 protein 
expression with stage, grade, and HER2/ER/PR expression. High NM23-H1 expression 
was associated with smaller tumor size, lower stage, and in some cases, lower grade 
[111, 112]. Overall, there was no correlation with NM23-H1 and HER2 expression [113], 
whereas, although not significant, there was a trend towards a positive correlation 
between NM23-H1 and ER expression [111-114]. Interestingly, findings which oppose 
the data mentioned above have documented higher NM23-H1 mRNA and protein levels 
associate with higher grades [112, 115], larger tumors [113] and decreased survival 
[115]. Therefore, due to conflicting data in the literature and the lack of statistical 
significance for the data in some of these studies, it is worthwhile to examine NM23-H1 
protein levels in melanoma and breast cancer tumor tissue to determine whether NM23-
H1 expression could serve as a prognostic marker.   
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In summary, examination of c-Abl/Arg kinase activity and NM23-H1 expression in 
melanoma and breast cancer primary tumors will provide a better understanding of the 
roles these proteins play in tumor progression and metastasis. Therefore, in this 
Chapter, we will evaluate whether c-Abl/Arg activity and NM23-H1 expression are 
correlated within particular disease subtypes in primary melanoma and breast cancer 
tissue.  
Materials and Methods 
Immunohistochemistry 
Tissue microarrays (Biomax BR1502, BR10010a, BC08118, ME1003 and NCI 
melanoma progression array) were incubated 60°c overnight. All of the following steps 
were performed at room temperature unless otherwise noted. Slides were rehydrated 
sequentially in xylene and ethanol (100%, 95%, 70%) for 5’ (x3) and subsequently rinsed 
in deionized water. Endogenous peroxidase activity was blocked (Dako K4010) for 10’ 
followed by antigen retrieval in Diva Decloaking solution (Biocare Medical) within a 
Biocare Medical Decloaking Chamber (30” at 125°c, 10” at 90°c). After cooling for 10’, 
slides were rinsed in deionized water, and left in TBST buffer (Dako S3306) for 5’. 
Primary antibody was diluted in antibody diluent (Dako S0809) and incubated for 2 
hours. Antibodies used were pCrk/CrkL (1:10, Cell signaling 3181), NM23-H1 (1:75, Cell 
Signaling D98), or negative control (Dako N1699). After being washed 3x in TBST and 
left for 5’ the slides were incubated for 30’ in Dako Envision+ System-HRP (K4010). 
After being washed 3x in TBST, left for 5’, the slides were incubated for 5-10’ in either 
Diaminobenzine (DAB, (brown color) Dako 4011), for breast cancer slides, or AEC+ Red 
(Dako K3461) was used for melanoma slides in order to be able to differentiate between 
chromagen and brown melanin pigmentation. The DAB/AEC+ chromagen was 
deactivated in tap water and subsequently dipped in hematoxylin stain (Dako S3302), 
deionized water, bluing Reagent (Richard-Allan Scientific), and again deionized water. 
For the DAB chromagen, slides were dehydrated sequentially in ethanol (70%, 95%, 
100%) and xylene for 5’ (2x), and mounted in xylene-based mount (Vector H5000). For 
AEC+ chromagen slides, the dehydration steps were bypassed and the slides were 
immediately mounted in aqueous mountant (Vector H5501). A pathologist (Michael 
Cibull, M.D., Dana Richards, M.D., Janna Neltner, M.D.) blindly scored the slides. Each 
core was assigned intensity of staining (1-3+) and percentage of positively-staining 
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tumor cells. A score for each core was calculated by multiplying the intensity of stain by 
the percentage of positively-stained tumor cells.  
Statistics 
 One (single) sample T-tests, One-way Anovas, Chi squares and Fisher’s exact 
tests were all performed using the VassarStats website (http://vassarstats.net).   
Results 
c-Abl and Arg are Activated in Primary, Early-onset and Intermittent Sun-exposed 
Melanomas 
 In previous studies, our lab demonstrated that activated c-Abl and Arg promote 
invasion, in vitro, and metastasis, in vivo [56, 57]. Therefore, to determine if c-Abl/Arg 
activation is linked to progression in human melanoma primary tissue, we performed 
immunohistochemistry on a melanoma tissue microarray (TMA) (ME1003, Biomax).  To 
assess c-Abl/Arg activity we used an antibody against the phosphorylation sites on the 
c-Abl/Arg substrates Crk/CrkL (Figure 2.1a). A blinded pathologist read the cores 
assigning each core with intensity of stain (1-3+) and percentage of stained cells. We 
calculated a score for each core by multiplying the intensity of the stain by the 
percentage of positively-staining tumor cells.  We observed that 60% of primary 
melanomas had high pCrk/CrkL staining in comparison to only 33% of the benign nevi 
(Figure2.2a, Table 2.1).  These results were confirmed using a second melanoma TMA 
obtained from NCI, which showed 41% positive staining in melanomas vs. 16% in nevi 
(Figure 2.2 a,b). We also observed increased pCrk/CrkL scores in primary tumor, lymph 
metastases and organ metastases in comparison to benign nevi (Figure 2.2b), 
suggesting that c-Abl and Arg are likely to have a role in promoting melanoma tumor 
progression to a metastatic phenotype.   
Next, to determine if c-Abl/Arg activity correlates with patient age in primary 
melanomas, we assessed pCrk/CrkL staining within the following age groups: young (39 
years and younger), middle-aged (40-59 years) and elderly (60 years and older). 
Although not significant, we found a trend towards higher pCrk/CrkL staining in the 
young age group as 86% of cores had intense staining whereas only 47% of the elderly 
age group cores had intense staining (Figure 2.2c, Table 2.1). These data suggest that 
early-onset melanoma could be driven, in part, by activated c-Abl and Arg. Additionally, 
we examined c-Abl and Arg activity in melanoma sun-exposure subtypes and observed  
that mucosal melanomas had the largest percentage of cores with intense pCrk/Crk
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Figure 2.1 pCrk/CrkL Staining in Primary Melanomas  
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Figure 2.1 pCrk/CrkL staining in primary melanomas. (a, b) Melanoma tissue 
microarrays were stained with pCrk/CrkL or IgG antibody and visualized with Dako 
AEC+ Red chromagen. (a) ME1003 (Biomax) TMA incubated in normal rabbit serum 
(NRS) or phospho-Crk/CrkL antibody, 400x magnification. (b) Representative regions of 
a large NCI tissue microarray stained with pCrk/CrkL antibody. 
 27 
Figure 2.2 c-Abl/Arg Activation in Primary Melanoma Tissue  
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Figure 2.2 c-Abl/Arg activation in primary melanoma tissue.  (a-d) Melanoma tissue 
microarrays were stained with pCrk/CrkL (Y221/Y207) or IgG antibody and visualized 
with Dako AEC+ Red chromagen and blindly read by a pathologists Michael L. Cibull, 
M.D. (ME1003) and Dana Richards, M.D. (NCI Array). Cores of bad quality were not 
scored. Score= intensity (1-3+) x proportion of positively stained tumor cells. (a,c,d) 
Percentage of cores with high and low pCrk/CrkL staining was graphed from ME1003 (a, 
c, d) and NCI melanoma TMA (a) . Cores were scored as high if the score was ≥1.4 (a,c) 
p-values obtained with Fisher’s Exact Test. (b) Average scores from a large NCI 
melanoma TMA were graphed. Bracket indicates overall difference among groups: 
**p=<0.01 with one way Anova.  
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 Table 2.1 c-Abl/Arg Activation in Primary Melanoma Tissue  
Tumor Type! Total n! High pCrk/
CrkL Score!
Low pCrk/
CrkL Score!
p-value!
Benign Nevi! 18! 6 (33%)! 12!
Primary 
Melanomas!
48! 29 (60%)! 19!
Lymph Node 
Metastases!
19! 9 (47%)! 10!
Age!
≤39! 7! 6 (86%)! 1!
40-59! 26! 16 (62%)! 10!
≥60! 15! 7 (47 %)! 8!
Sun-Exposure!
Chronic! 2! 1 (50%)! 1!
Intermittent! 28! 17 (61%)! 11!
Minimally 
Exposed!
13! 7 (54%)! 6!
Mucosal! 5! 4 (80%)! 1!
0.04!
0.25!
 
 
Melanoma tissue microarray (ME1003, Biomax) stained with pCrk/CrkL (Y221/Y207) 
antibody and visualized with Dako AEC+ Red chromagen was blindly scored by 
pathologist Michael L. Cibull, M.D. Scores described in Figure 2.2 legend. p-value is with 
Fisher’s Exact test. Percentages are % of cores staining high for pCrk/CrkL in each 
tumor type.   
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staining (80%) followed by melanomas of intermittent sun-exposure (61%) and the 
lowest percentage of positive cases were observed in melanomas from minimal sun-
exposed (54%) and chronically sun exposed (50%) areas (Figure 2.2d, Table 2.1). Early-
onset melanomas often arise from intermittently-sun exposed areas; therefore intense 
pCrk/CrkL staining in both of these melanoma subtypes suggests c-Abl/Arg activity could 
promote early-onset melanoma or are the result of genetic events that occur during the 
development of these melanomas. 
c-Abl and Arg are Activated in High-grade and Triple-negative Breast Cancer 
 Previously, we found that in addition to promoting invasion, c-Abl and Arg 
activation was highest in invasive breast cancer cell lines compared to non-invasive lines 
[89]. Therefore, we investigated whether c-Abl and Arg activity is increased in 
aggressive, invasive, high-grade breast cancers. We stained BC08118 and BR1502 
breast cancer TMAs (Biomax) with pCrk/CrkL antibody (Figure 2.3a) and found that 
Grade III tumors had a significantly higher percentage of intensely staining cores (17%) 
as compared to Grade I tumors (0%) (Figure 2.3b, Table 2.2). To determine whether c-
Abl/Arg activation is more frequent in a particular breast cancer subtype, we stained 
another TMA (BR10010a, Biomax) which contained clinical information including ER, PR 
and HER2 status. Although not significant due to small sample numbers, we observed a 
trend towards stronger pCrk/CrkL staining in the triple-negative cores as compared to 
HER2+ and ER/PR+ samples, which mostly stained weakly or moderately (Figure 2.3c, 
Table 2.2). These data suggest c-Abl and Arg could potentially be therapeutic targets in 
triple-negative breast cancer, which currently is the most difficult subclass to treat due to 
proteins not targeted by traditional chemotherapeutic drugs drive the cancers. 
To determine if c-Abl and Arg activation promotes metastasis in breast cancer, 
we compared pCrk/CrkL staining intensity in breast cancer metastases with their 
matched primary tumor tissue. Although not statistically significant, the majority of 
metastases had higher pCrk/CrkL staining than their matched primary tumor tissue 
(Figure 2.3d), suggesting tumors with c-Abl/Arg activation might be more likely to invade 
and metastasize. 
NM23-H1 Expression is Decreased in Benign Nevi, Early-onset and Intermittent Sun-
exposed Melanomas 
 To examine whether NM23-H1 expression levels vary in benign nevi, primary 
melanoma tumors, and metastases, we stained the melanoma ME1003 TMA (Biomax)
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Figure 2.3 c-Abl/Arg Activation in Matched Primary and Metastatic Breast Cancers  
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Figure 2.3 c-Abl/Arg activation in matched primary and metastatic breast cancers. 
(a-d) Breast tissue microarrays were stained with pCrk/CrkL or IgG antibody and 
visualized with DAB chromagen. Slides were blindly read by pathologist Michael L. 
Cibull, M.D. Score= intensity (1-3+) * proportion of positively stained tumor cells. (a) 
Breast cancers representing weak, moderate and strong intensity staining are shown 
(TMA: BC08118).  (b) TMAs BC08118 and BR1502, scores >2.7  were scored as high 
and <1.4 scored as low (c) TMA BR1001a, scores >2.5  were scored as high and <1 
scored as low.  (b,c) p-value with Fisher’s Exact Test d) Difference between the 
pCrk/CrkL scores from primary tumors and matched metastases (left). Percentage of 
metastatic cores with increased, decreased or no change in pCrk/CrkL staining as 
compared to primary tumor cores shown in pie chart (right) (TMA:BR10010a). p=0.34 
using a  single sample t-test. 
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 Table 2.2 c-Abl/Arg Activation in Breast Cancer Subtypes 
Grade! Total n! High !
pcCrk/CrkL 
Score!
Medium!
 pCrk/CrkL 
Score!
Low!
 pCrk/CrkL 
Score!
!
p-value!
 I! 26! 0 (0%)! 13! 13 (50%)!
II! 63! 6 (9.5%)! 27! 30 (48%)!
 III! 71! 12 (17%)! 13! 28 (39%)!
Tumor Type!
Triple 
Negative!
12! 2 (16%)! 4! 6 (50%)!
HER2+! 23! 0 (0%)! 10! 13 (57%)!
ER/PR+! 24! 0 (0%)! 8! 16 (67%)!
Table 2.2 Association of pCrk/CrkL with breast cancer characteristics 
0.016!
0.18!
 
Breast cancer tissue microarrays were stained with pCrk/CrkL antibody and visualized 
with DAB chromagen. Slides were blindly read by pathologist Michael L. Cibull, M.D. 
Scores described in Figure 2.3 legend. p-value is with Fisher’s Exact test.  
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with an NM23-H1 antibody (Figure2.4a). Overall, primary melanoma cores had more 
intensely staining cores as compared to benign nevi cores, which  primarily had weak 
staining (Figure 2.5a, left; Table 2.3). In fact, the average NM23-H1 score within the 
primary melanomas was 9x that of the nevi (Figure 2.5a, right). In addition, the lymph 
node metastases, had 10% fewer cores staining intensely with NM23-H1 antibody as 
compared to the primary melanomas (Figure 2.5a, left; Table 2.3), and there was no 
significant difference between the mean scores of the two groups (Figure 2.5a, right), 
which was unexpected given the known anti-metastatic properties of NM23-H1. 
 There are few studies that have investigated whether NM23-H1 expression 
correlates with age in primary melanoma tissue. We found that melanomas from 
younger patients have less NM23-H1 staining as compared to those derived from older 
individuals  (Figure 2.5b, left; Table 2.3). Additionally, we found the average NM23-H1 
score of the melanomas from the younger age group to be significantly lower than both 
the middle age and elderly age groups (Figure 2.5b, right), which indicates that NM23-
H1 downregulation may be necessary for the progression of early-onset melanoma or 
may result from genetic changes that occur in this subgroup. This is in contrast to 
pCrk/CrkL staining, which was highest in melanomas from the younger age group, 
suggesting that there may be a possible inverse correlation between c-Abl/Arg activity 
and NM23-H1 in primary melanoma tissue (assessed in Chapter 3).  
 Finally, we determined whether NM23-H1 expression varies among melanoma 
sun-exposure subtypes. Chronic sun-exposed melanomas had the smallest percentage 
of intensely staining cores (0%) followed by melanomas in the intermittent sun-exposure 
(28%) category as compared to more intense staining in melanomas from minimally sun-
exposed areas (38%) and mucosal melanomas (50%) (Figure 2.5c, Table 2.3). As 
previously mentioned, early-onset melanoma tumors are usually of the intermittent sun-
exposed subtype. Therefore, our data demonstrating low NM23-H1 staining in both 
intermittent sun-exposed melanomas and in melanomas from younger patients 
strengthens the hypothesis that NM23-H1 loss may be a contributing factor in the 
development of early-onset melanoma.  
NM23-H1 Expression is Decreased in High-grade, Advanced-stage Breast Cancer and 
is Positively Correlated with ER Expression 
In an attempt to confirm or deny conflicting reports regarding the expression of 
NM23-H1 in breast cancer, we stained breast cancer TMAs BR01001a and BC08118 
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Figure 2.4 NM23-H1 Expression  in Primary Melanomas and Breast Cancers  
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Figure 2.4 NM23-H1 expression in primary melanomas and breast cancers. (a) 
ME1003 melanoma tissue microarrays were stained with NM23 or IgG antibody and 
visualized with Dako Red chromagen (left). Benign nevi and representative weak, 
moderate, and strong staining primary tumors are shown (right). (b) Breast cancer tissue 
microarray BR1001a was stained with NM23 or IgG antibody and visualized with DAB 
chromagen. Breast cancer representing weak, moderate and strong NM23 staining are 
shown. 400x maginification. 
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Figure 2.5 NM23-H1 Expression in Primary Melanomas  
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Figure 2.5 NM23-H1 expression in primary melanomas. (a-c) ME1003 melanoma 
tissue microarrays were stained with NM23 or IgG antibody and visualized with Dako 
Red chromagen. Cores of bad quality were not scored. Slides were blindly read by 
pathologist Michael L. Cibull, M.D.  Score= intensity (1-3+) * proportion of positively 
stained tumor cells. Cores were scored as either low or high staining NM23 (left) and the 
average NM23 score of each group was determined (right) Cores were scored as high if 
the score was ≥1.4. (b, left) p=0.13 with Fishers exact test. (a, b right) *p=<.01 with 
Single Sample T-test. 
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Table 2.3 NM23-H1 Expression in Primary Melanomas 
Tumor Type! Total n! High NM23-H1! Low NM23-H1!
!
p-value!
Benign Nevi! 18! 0 (0%)! 18!
Primary 
Melanomas!
48! 15 (31%)! 33!
Lymph Node 
Metastases!
19! 4 (21%)! 15!
Age!
!
≤39! 7! 0 (0%)! 7!
40-59! 25! 10 (38%)! 16!
≥60! 16! 6 (40%)! 9!
Sun-Exposure!
Chronic! 2! 0 (0%)! 2!
Intermittent! 28! 8 (28%)! 20!
Minimally 
Exposed!
13! 5 (38%)! 8!
Mucosal! 5! 2 (50%)! 3!
0.13!
0.006!
 
 
Melanoma tissue microarray (ME1003, Biomax), stained with NM23 antibody and 
visualized with Dako AEC+ Red chromagen, and blindly read by pathologist Michael L. 
Cibull, M.D. Scores described in Figure 2.5 legend. p-value is with Fisher’s Exact Test.  
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(Biomax) with an NM23-H1 antibody (Figure 2.4b).  We found no significant correlation 
between NM23-H1 expression and grade (Figure 2.6a); however, we observed a trend 
towards an inverse correlation between NM23-H1 expression and stage  (Figure 2.6b, 
Table 2.4), confirming studies linking higher NM23-H1 expression to better survival 
[100]. Additionally, ER/PR+ and HER2+ breast cancers had the largest percentage of 
cores with intense NM23-H1 staining (25% and 23% respectively) as compared to triple-
negative cores, which had moderate and weak staining exclusively (0% intense staining) 
(Figure 2.6c, Table 2.4). Consistent with other reports [111, 112, 114], we found a 
significantly higher percentage of ER+ tumors stained intensely with NM23-H1 antibody 
(33%) as compared to the ER- group (6%) (Figure 2.6d, Table 2.4). These data suggest 
a potential role for NM23-H1 in regulation of ER expression or vice versa. 
 
Discussion 
 
 In this Chapter, we provide evidence for increased c-Abl and Arg activity in 
melanoma primary tumors compared to benign nevi, as assessed by pCrk/CrkL staining. 
This is the first report demonstrating increased c-Abl/Arg activity in primary melanomas 
as previous studies only analyzed c-Abl and Arg protein expression. These findings 
support our in vitro and in vivo data demonstrating that c-Abl/Arg activity is required for 
melanoma invasion and metastasis [56, 57]. Immunohistological staining for NM23-H1 in 
melanoma tissue revealed a trend similar to pCrk/CrkL in that NM23-H1 expression was 
increased in primary melanomas as compared to benign nevi.  Although overexpression 
of a metastasis suppressor in primary tumors was unexpected, these data are consistent 
with reports in the literature demonstrating increased NM23-H1 mRNA levels in 
melanoma primary tumors compared to nevi [103]. Likewise, in colorectal carcinoma, 
lower stage tumors (0-II) had much higher NM23-H1 expression as compared to normal 
mucosa [116]. Interestingly, in advanced colorectal tumors (stage III-IV), NM23-H1 
expression was significantly decreased compared to lower stage tumors (0-II) [116], 
suggesting that NM23-H1 expression is likely upregulated in the initial stages of 
tumorigenesis and subsequently downregulated during progression. In support of this 
hypothesis, NM23-H1 has been shown to promote proliferation and DNA synthesis in 
breast cancer primary tumor cells [117]. Furthermore, a positive correlation has been 
observed between NM23-H1 expression and proliferation in primary neoplastic tumors, 
however this is likely occurring exclusively in early stage tumors as no correlation was 
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Figure 2.6 NM23 Expression in Primary Breast Cancers  
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Figure 2.6 NM23 expression in primary breast cancers. (a-d) Breast tissue 
microarrays were stained with NM23 antibody and visualized with DAB chromagen. 
Slides were blindly read by pathologist Michael L. Cibull, M.D. Cores of bad quality were 
not scored. Score= intensity (1-3+) * proportion of positively stained tumor cells. (a,b) 
TMAs BC08118 and BR1502 (Biomax), scores >1.8  were scored as high and  ≤ 1.8 
scored as low.  (c,d) TMA BR1001a (Biomax) Scores >2.5 were scored as high and < 1 
scored as low. p-values are Fisher’s exact test. 
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Table 2.4 NM23-H1 Expression in Primary Breast Cancers  
Tumor 
Type!
Triple 
Negative!
12! 0 (0%)! 8! 4 (33%)!
HER2+! 22! 5 (23%)! 9! 8 (36%)!
ER/PR+! 24! 6 (25%)! 9! 9 (38%)!
Grade! Total n! High NM23-
H1!
Medium 
NM23-H1!
!
High !
NM23-H1!
!
p-Value!
 I! 22! 11 (50%)! 11!
II! 82! 38 (46%)! 44!
 III! 18! 7 (39%)! 11!
Stage!
!
I! 17! 12 (71%)! 5!
II! 99! 57 (58%)! 42!
III! 24! 11 (42%)! 13!
Tumor 
Type!
ER-! 32! 2 (6%)! 17! 13 (41%)!
ER +! 18! 6 (33%)! 6! 6 (33%)!
0.04b!
0.76a!
0.28a!
0.32a!
 
Breast cancer tissue microarrays were stained with NM23-H1 antibody and visualized 
with DAB chromagen. Slides were blindly read by pathologist Michael L. Cibull, M.D. 
Scores described in Figure 2.6 legend. p-values with Fisher’s Exact Testa or Chi Square 
Analysisb.  
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observed in primary tumors known to metastasize [118] further supporting a role for 
NM23-H1 in early stage tumorigenesis. The molecular switch for NM23-H1 
downregulation in advanced stage tumors is unknown, however we observed increased 
c-Abl/Arg activity in tumor types containing low NM23-H1 expression such as age and 
sun-exposure in melanomas, and grade and receptor expression subtypes in breast 
cancer. These data suggest that the activities of c-Abl/Arg and NM23-H1 may be linked 
during melanoma and breast cancer progression (investigated in Chapter 3). 
We observed only a slight decrease in the percentage of cores (10%) staining 
intensely with NM23-H1 antibody in melanoma lymph node metastases as compared to 
primary tumors. We expected a more significant decrease in NM23-H1 expression in 
metastases given that NM23-H1 has metastasis suppressor functions. We believe that 
these unexpected results are due to ascertainment bias, as most of the lymph node 
metastases were derived from melanomas in minimal (79%) or chronic (21%) sun-
exposure subtypes, which tend to have higher NM23-H1 expression than the other 
subtypes. Additionally, minimal and chronic sun-exposed melanomas often have cKIT 
upregulation and activation [7, 119]. Therefore we hypothesize that NM23-H1 and cKIT 
expression may be related. Although NM23-H1 has been linked to transcriptional 
activation of EBNA3C (Epstein-Barr virus nuclear antigen 3C) [120], its role in 
transcription remains undefined. However, NM23-H2, which shares 88% homology with 
NM23-H1 at the protein level, is a transcriptional activator and binds G4 motifs within the 
c-Myc promoter [121, 122]. Therefore, given that the cKIT promoter also contains G4 
motifs [123], and NM23-H1 is highly homologous to NM23-H2, we hypothesize that 
NM23-H1 may bind G4 motifs within the cKIT promoter thereby promoting cKIT 
overexpression in minimally and chronically sun-exposed melanomas.  
Interestingly, we observed higher c-Abl and Arg activity in melanomas from 
young patients (<40 years of age) as compared to older patients. Early-onset 
melanomas often arise from areas with sunburn-induced intermittent sun-exposure 
caused by frequent tanning bed use in younger individuals [124, 125]. Intermittent sun-
exposure does not activate the protective tanning response often seen with chronic sun-
exposure and instead leads to production of reactive oxygen species, which causes 
genetic mutations, such as BRAF [1, 7]. Our observation of high c-Abl and Arg activity in 
melanomas from young patients and in melanomas from the intermittent sun-exposed 
subtype suggests c-Abl and Arg may be involved in promoting early-onset melanomas 
caused by intermittent sun-exposure.  Given that c-Abl/Arg activity is high and BRAF 
 40 
mutations are common in this melanoma subtype, it is possible that activities of BRAF 
and c-Abl/Arg may be linked. 
In contrast to c-Abl and Arg activity being increased in early-onset melanoma, we 
observed a significant decrease in NM23-H1 expression in melanomas from young 
patients. As mentioned above, early-onset melanomas typically arise from areas of 
intermittent sun-exposure, and contain genetic mutations such as BRAF [1, 124]. Low 
NM23-H1 expression in early-onset melanoma is further supported by our observation 
that 72% of intermittent sun exposed melanomas (the majority of which tend to have 
early onset) also have low NM23-H1 expression. NM23-H1 functions in DNA repair as 
NM23-H1 activity (NDPK, HisK and 3’->5’ exonuclease) was found to be essential for the 
repair of polymerase blocking lesions induced by UV radiation and, additionally, deletion 
of mouse NM23-M1/M2 was shown to increase UV- induced metastatic lesions, in vivo 
[79, 80]. Therefore, the low NM23-H1 expression that we observed in intermittent sun-
exposed, early-onset melanomas, which are prone to genetic mutations, may contribute 
to melanoma progression due to lack of NM23-H1-mediated DNA repair.  
 In addition to elevated c-Abl/Arg activity in primary melanomas, we also observed 
a significant increase in activity with increasing breast cancer grade. Increased grade 
has been linked with decreased disease-free survival and together with stage, is highly 
prognostic [19, 20]. These data suggest that, in addition to grade and stage, elevated c-
Abl/Arg activity also could potentially be a prognostic marker for breast cancer. In 
addition, we found the largest percentage of cores staining intensely for c-Abl/Arg 
activity were classified as triple-negative, complementing our previously published data 
in breast cancer cell lines, demonstrating that Arg activity was highest in triple-negative 
lines and c-Abl activity was highest in triple-negative and HER2+ cell lines [56]. 
Considering the trends we observed of increased c-Abl/Arg activity in high-grade, 
ER/PR-negative tumors, we hypothesize that activated c-Abl and Arg promote an 
aggressive, triple-negative phenotype. Furthermore, although not significant, we found 
that the majority of lymph node metastases had higher pCrk/CrkL staining (c-Abl/Arg 
activity) as compared to the matched primary tumors, further supporting a role for c-
Abl/Arg activity in promoting an aggressive tumor type leading to metastasis. 
Surprisingly, we found no significant correlation between NM23-H1 expression 
and grade in primary breast cancers. However, we did observe a trend towards 
decreased NM23-H1 expression with increasing stage that will likely approach 
significance with increased sample numbers. Breast cancer grade is indicative of tumor 
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growth rate whereas tumor staging not only takes into account primary tumor size but 
spread to the lymph nodes and distant organ sites. Our previously mentioned data 
demonstrated increased NM23-H1 expression in primary tumors as compared to benign 
nevi indicated NM23-H1 may promote the early stages of tumorigenesis, therefore we 
were surprised to observe no correlation between NM23-H1 expression and grade. 
However, decreased NM23-H1 expression with breast cancer stage is consistent with 
our melanoma data in which we observed decreased NM23-H1 expression in lymph 
node metastases as compared to primary tumors. These data suggest that the 
downregulation of NM23-H1 expression is required for progression to an advanced 
stage tumor.  
We also observed a significant positive correlation between NM23-H1 and 
estrogen receptor expression confirming the trend previously reported by other 
investigators [111, 112, 114]. This data supports a model in which the ER increases 
NM23-H1 expression levels.  In fact, it has been previously reported that ERα reduces 
invasion via transcriptional upregulation of NM23-H1 expression in several breast cancer 
cell lines, including MCF-7 cells [85]. Interestingly, also in MCF-7 cells, another group 
found that increased NM23-H1 expression decreased transactivation of ERα [78], 
suggesting a potential feedback mechanism between ERα and NM23-H1. Although ERα 
promotes proliferation, it has also been shown to suppress cell motility and invasion, 
thus making ER+ tumors less aggressive than triple-negative tumors.  Taken together, 
these data indicate that ER may upregulate NM23-H1 in early stage tumors to promote 
proliferation, and downregulation of ERα in advanced stage tumors may lead to 
decreased NM23-H1 expression, thereby promoting an aggressive, metastatic 
phenotype.   
In summary, in this Chapter we showed that increased c-Abl and Arg activity 
correlates with progression to an aggressive tumor type in two solid tumor cancers. 
Based on our observations in primary melanoma and breast cancer tissue discussed in 
this chapter, we hypothesize two mechanisms by which c-Abl/Arg promote progression 
and metastasis in these cancers. First, we propose activation of c-Abl/Arg kinases in 
intermittently sun-exposed melanomas inhibits DNA repair mechanisms via 
downregulation of NM23-H1 expression leading to tumor progressing mutations.  
Second, we hypothesize that c-Abl/Arg activation in late stage breast cancers 
subsequently causing loss of NM23-H1 expression thereby leading to an aggressive, 
triple-negative tumor type. In conjunction with our already published in vitro and in vivo 
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data, these data presented in this Chapter support the use of pCrk/CrkL and NM23-H1 
expression as diagnostic markers for early-onset, intermittent melanomas and triple-
negative breast cancers. 
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Chapter 3:  c-Abl and Arg Induce Degradation of the 
NM23-H1 Metastasis Suppressor 
Introduction 
Metastatic spread of the primary tumor to a secondary location is the primary 
cause of mortality in melanoma and breast cancer patients. Metastasis requires the cell 
to detach from the primary tumor, invade the basement membrane, degrade the 
extracellular matrix, travel through the vasculature, and survive and proliferate at a 
secondary site. This process is driven by upregulation and activation of oncogenes, 
which promote proliferation, anchorage independent growth, cell-survival, migration and 
invasion [126]. In conjunction with oncogenes, downregulation of metastasis 
suppressors promotes these pro-metastatic mechanisms. Resistance to conventional 
therapies often results in metastasis and death; therefore, discovery of alternative 
treatment options for patients is necessary to promote survival.  
 The Abl family kinases, c-Abl and Arg, drive the progression of chronic 
myelogenous leukemia in which the BCR gene is translocated next to the Abl gene 
creating a constitutively active kinase [49]. Our laboratory was the first to identify the role 
of these kinases in solid tumor progression. We demonstrated that c-Abl and Arg are 
highly activated in melanoma and breast cancer cell lines promoting proliferation, 
anchorage-independent growth, survival, invasion and metastasis [56, 61]. We also 
demonstrated that c-Abl/Arg promote invasion via the upregulation and activation of 
MMP1, MMP3, and MT1-MMP [57]. However, recombinant MMPs only partially rescued 
the block in invasion observed following c-Abl/Arg knockdown [57], suggesting that c-
Abl/Arg likely promote invasion via multiple mechanisms.  
 NM23-H1 was the first gene identified as a metastasis suppressor gene due to 
the observation that metastatic murine cell lines had low NM23-H1 mRNA expression as 
compared to non-metastatic cell lines having high NM23-H1 mRNA expression [69]. 
Furthermore, transfection of NM23-H1 into invasive melanoma cells reduced motility and 
metastasis and high NM23-H1 expression was demonstrated to correlate with better 
prognosis and increased survival [70-72, 100, 107]. Three NM23-H1 biological functions 
have been identified: nucleoside diphosphate kinase activity, histidine kinase activity, 
and a 3’->5’ exonuclease function [68, 73].  Most of the research on NM23-H1 has 
focused on binding partners and mechanisms of metastasis suppression; therefore, very 
little information has been obtained regarding upstream regulators of NM23-H1. In fact, 
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the mechanism of NM23-H1 protein turnover and downregulation has yet to be 
identified. Given the decreased incidence of metastasis in tumors with high NM23-H1 
expression, identification of the mechanisms that regulate NM23-H1 expression could 
help define new treatment options that increase NM23-H1 expression and benefit 
patients.   
 In Chapter two, we analyzed NM23-H1 expression and c-Abl/Arg activity in 
melanoma and breast cancer primary tissue. Interestingly, in melanoma tissue, we 
observed high c-Abl/Arg activity in tumors from younger patients and with intermittent 
sun-exposure, whereas NM23-H1 expression was low in these same subtypes. 
Furthermore, in breast cancer tissue, in tumors classified as triple-negative and high-
grade we observed c-Abl/Arg activity to be high and NM23-H1 expression to be low. 
These data suggest c-Abl/Arg activity and NM23-H1 may be inversely correlated in 
melanoma and breast cancer primary tumors, suggesting a potential link between c-
Abl/Arg and NM23-H1.  
 Given that c-Abl/Arg and NM23-H1 have opposing functions in cancer 
progression led us to hypothesize that c-Abl/Arg downregulate NM23-H1 expression to 
promote invasion and metastasis. Therefore, in this Chapter, we investigate the 
regulation of NM23-H1 protein expression, the novel link between c-Abl/Arg activity and 
NM23-H1, and the role this mechanism plays in invasion and metastasis.   
Materials and Methods 
Cell Lines and Reagents  
 MDA-MB-435s cells were obtained from University of North Carolina Tissue 
Culture Facility (Chapel Hill, NC), BT-549 cells were from Rolf Craven (University of 
Kentucky), and A375 were from Dr. Suyan Huang (M.D. Anderson Cancer Center, 
Houston, TX). All sources obtained the lines from ATCC (Manassas, VA). 435s is 
genetically identical to melanoma M14, and BT-549 cells are identical to ATCC BT-549 
[127]. WM melanoma cells were obtained from Dr. Meenhard Herlyn (Wistar Institute, 
Philadephia, PA). A375 was from Dr. Suyun Huang (M.D. Anderson Cancer Center, 
Houston, TX). Primary melanoma cells (HEMn) were purchased from Invitrogen 
(Carlsbad, CA) and MCF-7 cells were gifts from Dr. Vivek Rangnekar (University of 
Kentucky, Lexington, KY). Breast cancer cell lines were obtained from University of 
North Carolina Tissue Culture Facility (Chapel Hill, NC). Human mammary epithelial 
cells (HMEC) were purchased from Cambrex (Baltimore, MD).  
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 The following antibodies were purchased commercially: c-Abl (K12; kinase 
assay), Arg (9H5-western blot), α-tubulin, LAMP1, cathepsin L1, HRP-conjugated 
secondary antibodies (Santa Cruz Biotechnology; Santa Cruz, CA); pCrk/CrkL 
(Y221/Y207), c-Abl (8E9; western blotting), GAPDH, (BD Biosciences; Chicago, IL); 
EEA1, Rab7, p27, NM23-H1 (D98-immunohistochemistry, D14H1-western blotting), (Cell 
Signaling; Danvers, MA); cathepsin B (R&D; Minneapolis, MN), cyclin D1 (Millipore; 
Billerica, MA); Rab5 (Abcam, Cambridge, England) and β-actin (Sigma Aldrich, St. 
Louis, MO). The Arg kinase Assay Antibody was previously described [47]. Imatinib and 
nilotinib were provided by Novartis (Basel, Switzerland); IGF-1 was from Upstate 
Biotechnology (Charlottesville, VA), matrigel invasion chambers were from BD 
Biosciences; chloroquine and ammonium chloride were from Sigma; MG132 and 
proteasome inhibitor I (PS1) were from Millipore; and E64d was from Tocris 
(Minneapolis, MN).  
Western Blots and Kinase Assay 
Cell lines were lysed in RIPA buffer (50mM Tris pH 7.5, 150mM NaCl, 1% triton-X 100, 
0.1% SDS, 1% sodium deoxycholate, 1mM pefabloc, 1mM sodium orthovanadate, 
25mM sodium fluoride, 10µg/ml leupeptin, 10µg/ml aprotinin, 10µg/mL pepstatin). Total 
protein was quantitated using Lowry (Biorad, Hercules, CA) or Pierce BCA protein assay 
(Thermo Scientific, Waltham, MA). Equal protein was loaded onto SDS-PAGE gels. 
Immunoblotting was performed using antibody manufacturer protocols. Kinase assays 
were performed as previously described [47]. Bands were quantified using ImageQuant 
(GE Healthcare, Piccataway, NL) or ImageJ (NIH, Bethesda, MA). 
Transfection and RNAi 
Cells were plated in 60mm dishes and transfected two consecutive days to increase 
knockdown efficiency. Cells were transfected with the following siRNAs (Applied 
Biosystems; Carlsbad, CA) using Lipofectamine 2000 (Invitrogen). Abl #1,2 (1336, s886, 
respectively; 20nM), Arg #1,2 (1478, s872; 20nM), NM23-H1 (s9588; 1nM); cathepsin L1 
(s3753; 5nM); cathepsin B (s3740; 5nM), scrambled control #1 (control for non-silencer 
select), silencer select scrambled #1 (for silencer select). Cells were infected with 
PLK01-NM23-H1 shRNA (182s1c1) or PLK01 non-targeted shRNA Mission lentiviruses 
(MOI6; Sigma;12h; 8mg/ml polybrene) and selected with puromycin (1mg/ml). 
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RT-PCR 
Semi-quantitative. Cells were plated in 60mm dishes and treated per experiments. RNA 
was extracted using RNAeasy kit (Qiagen, Valencia, CA). RNA was then DNase treated 
with TURBO DNA-free (Life Technologies, Grand Island, NY). RNA was reverse 
transcribed into cDNA using SuperScript reverse transcriptase and random primers 
(Invitrogen, Carlsbad, CA) and PCR was performed using specific primers (below) 
together with β-actin control primers. Aliquots were taken at cycles 27-35 to check for 
linearity. Bands were quantified with ImageQuant (GE Healthcare) and normalized to b-
actin. c-Abl, Arg and β-actin primers were previously described [56].  
cathepsin B forward primer, 5’TGGACAAGAAAAGGCCTGGTT3’ 
cathepsin B reverse primer, 5’CCCAGTCAGTGTTCCAGGA3’ 
cathepsin L1 forward primer, 5’CTGTGAAGAATCAGGGTCAGTG3’ 
cathepsin L1 reverse primer, 5’CTGGCTGCTGAGGCAATTC3’.  
 
Real-Time RT-qPCR (Bio-Rad; Hercules, CA). DNase-treated cDNA (50ng; iScript; Bio-
Rad) was amplified using SYBER green and specific primers (500 ng, 40 cycles, 62oC 
annealing temperature). Results were analyzed with CFX Manager (Bio-Rad). Primers 
were designed and blasted with Primer Blast (NCBI website) to rule out homology to 
other genes. RPS13 was found to be the most stable reference gene out of five tested 
(RPS13, β-actin, HSP13, RPS11, and RP2).  
NM23-H1 forward primer, 5’CAGTGTTACCATCCCCGACC3’ 
NM23-H1 reverse primer, 5’CAACAATATGAAGTAACCAACTCA3’ 
RPS13 forward primer, 5’CGAAAGCATCTTGAGAGGAACA3’ 
RPS13 reverse primer, 5’GCACCACGTCCAATGACAT3' 
β-actin forward primer, 5’ GAGCACAGAGCCTCGCCTTT3’ 
β-actin reverse primer, 5’ CGAGCGCGGCGATATCATCA3’ 
HSP13 forward primer, 5’TCTGGGTATCGGAAAGCAAGCC3’ 
HSP13 reverse primer, 5’GTGCACTTCCTCAGGCATCTTG3’ 
RPS11 forward primer, 5’ GCCGAGACTATCTGCACTAC3’ 
RPS11 reverse primer, 5’ ATGTCCAGCCTCAGAACTTC3’ 
RP2 forward primer 5’GCACCACGTCCAATGACAT3’ 
RP2 reverse primer 5’GTGCGGCTGCTTCCATAA3’  
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Percoll-Gradient Fractionation  
Cells were plated to 60% confluency in six 150cm plates per treatment group. Plates 
were washed 2x in PBS+ (0.5mM MgCl2 and 1mM CaCl2) and scraped into PBS without 
MgCl2 and CaCl2. Cells were spun 5’, 1,200 RPM, 4°C. Cell pellets were resuspended in 
homogenization buffer (20mM HEPES, 150mM NaCl, 2mM CaCl2, pH 7.4, 1mM 
pefabloc, 1mM sodium orthovanadate, 25mM sodium fluoride, 10µg/ml leupeptin, 
10µg/ml aprotinin, 10µg/mL pepstatin). Cells were spun again as before, followed by 
dounce homogenization. Cells were spun again and supernatant was collected (PNS). A 
sample of the PNS was solubilized, and protein levels were determined using Pierce 
BCA protein assay (Thermo Scientific, Waltham, MA). Eleven mL of Percoll solution 
(10mM Tris pH 8.0, 150mM NaCl, 20% Percoll, +inhibitors) was added to a 12 mL 
centrifuge tube and equal PNS protein amounts across treatment groups added to top of 
Percoll solution. Tubes were centrifuged for 50’, 15,000RPM (20,000g), 4°c in a 70.1Ti 
fixed angle rotor (Beckman Coulter, Indianapolis, IN). Fractions (1mL) were collected 
and incubated in CHAPS (10mM final) for 1 hour. SDS-PAGE sample buffer (4x) was 
added to fractions, boiled for 5’ and supernatant collected. Equal volumes of fractions 
were loaded on an SDS-PAGE gel and immunoblotted  (EEA1, LAMP1, RAB7, NM23-
H1).  
Matrigel Boyden Chamber Invasion Assays  
Cells were serum-starved for 24hrs and treated with nilotinib for 8hrs. Cells were 
trypsinized and resuspended in invasion assay media (basal media + 1% BSA + 
vehicle/inhibitor) and washed 3x in invasion assay media. Invasion assay media was 
added to a well in a 24 well plate with 10nM IGF-1 added as a chemoattractant. The 
matrigel invasion chamber (BD Biosciences, Chicago, IL) was placed into the well, and 
2.5x105 cells were plated in the top of the chamber. After the cells were allowed to 
migrate through the matrigel for 48hr (37°C), the membrane was rinsed in PBS, cells on 
the upper surface of the membrane were removed, cells on the lower surface were fixed 
in methanol, stained (1% toluidine blue in 1% borax), and mounted on a slide. Cells on 
the lower surface were counted using a 20x objective.  
Lung Colonization/Metastasis Assays  
The metastasis assay is described in detail in Ganguly, et al. [57]. 435s-GFP/luciferase 
cells, were injected (2x106 cells/100ml Hanks Balanced Salt Solution; Invitrogen) into the 
tail vein of 7- 8-week old SCID-beige mice. Mice were treated with vehicle (0.5% 
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hydroxymethylcellulose/0.05% Tween-80) or nilotinib (33mg/kg in vehicle; b.i.d.) by oral 
gavage. Fluorescence was measured by IVIS Xenogen Spectrum (Caliper Life Sciences, 
Hopkinton, MA). Mice were euthanized on day 24 and lungs were removed, fixed in 
100% formalin, paraffin embedded (see below), sectioned and immunostained (see 
below) with pCrk/CrkL or NM23-H1 antibody, and scanned on an Aperio Scanscope. 
The University IACUC Committee approved all studies.  
Paraffin Embedding 
Formalin-fixed lungs were dehydrated in 70% ethanol, 100% ethanol, 1:1 ethanol/xylene, 
followed by 100% xylene for 2 hours at room temperature.  Lungs were placed in melted 
paraplast X-tra:xylene (1:1) for 1hr at 54oC followed by room temperature incubation 
overnight. Paraplast (100%) was then added to the tissue for 1h at 54oC, incubated at 
room temperature for 2h, paraffin was melted, and mounted at room temperature. The 
mounted lungs were sectioned on a ThermoShandon Finesse microtome (University of 
Kentucky Histology Facility) and stored in a desiccator for long-term storage. 
Immunohistochemistry  
Tissue microarrays (Biomax BR1502, BR10010a, BC08118, ME1003 and NCI 
melanoma progression array) were incubated at 60°C overnight. All of the following 
steps were performed at room temperature unless otherwise noted. Slides were 
rehydrated sequentially in xylene and ethanol (100%, 95%, 70%) for 5’ (x3) and 
subsequently rinsed in deionized water. Endogenous peroxidase activity was blocked 
(Dako K4010) for 10’ followed by antigen retrieval in Diva Decloaking solution (Biocare 
Medical) within a Biocare Medical Decloaking Chamber (30” at 125°c, 10” at 90°c). After 
cooling for 10’, slides were rinsed in deionized water, and left in TBST buffer (Dako 
S3306) for 5’. Primary antibody was diluted in antibody diluent (Dako S0809) and 
incubated for 2 hours. Antibodies used were pCrk/CrkL (1:10, Cell signaling 3181), 
NM23-H1 (1:75, Cell Signaling D98), or negative control (Dako N1699). After being 
washed 3x in TBST and left for 5’ the slides were incubated for 30’ in Dako Envision+ 
System-HRP (K4010). After being washed 3x in TBST, left for 5’, the slides were 
incubated for 5-10’ in either Diaminobenzine (DAB, (brown color) Dako 4011), for breast 
cancer slides, or AEC+ Red (Dako K3461) was used for melanoma slides in order to be 
able to differentiate between chromagen and brown melanin pigmentation. The 
DAB/AEC+ chromagen was deactivated in tap water and subsequently dipped in 
hematoxylin stain (Dako S3302), deionized water, bluing Reagent (Richard-Allan 
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Scientific), and again deionized water. For the DAB chromagen, slides were dehydrated 
sequentially in ethanol (70%, 95%, 100%) and xylene for 5’ (2x), and mounted in xylene-
based mount (Vector H5000). For AEC+ chromagen slides, the dehydration steps were 
bypassed and the slides were immediately mounted in aqueous mountant (Vector 
H5501). A pathologist (Michael Cibull, M.D.) blindly scored the slides. Each core was 
assigned intensity of staining (1-3+) and percentage of positively-staining tumor cells. A 
score for each core was calculated by multiplying the intensity of stain by the percentage 
of positively-stained tumor cells.  
Statistics 
 Statistical analyses were performed with SAS or the Vassar Website 
(http://vassarstats.net). Some data were normalized to vehicle or scrambled control, and 
analyzed with one-sample t-tests. Two-tailed values are shown.  0.01≤*p<0.05; 
0.001≤**p<0.01; ***p<0.001. 
Results  
Abl Family Kinases Downregulate NM23-H1 Expression 
c-Abl/Arg and NM23-H1 have opposing functions; therefore, we investigated if a 
correlation exists between c-Abl and Arg kinase activity and NM23-H1 expression in 
melanoma and breast cancer cell lines. We analyzed c-Abl and Arg activity indirectly, by 
examining phosphorylation of the c-Abl/Arg kinase substrate, pCrk/Crk, or we directly 
assessed c-Abl and Arg kinase activity by in vitro kinase activity assay utilizing GST-Crk 
as substrate in panels of melanoma and breast cancer cell lines, respectively. We 
observed NM23-H1 expression to be the lowest in cell lines with the highest c-Abl and 
Arg activity (Figure 3.1a,b). In fact, when we plotted pCrk/CrkL expression or c-Abl/Arg 
kinase activity against NM23-H1 protein expression we observed a significant negative 
correlation in both the melanoma and breast cancer cell line panels (Figure 
3.1a,b,bottom), indicating a potential link between Abl family kinase activity and NM23-
H1 expression. 
To determine if c-Abl and Arg lie upstream of NM23-H1, we transfected two 
independent siRNAs directed against c-Abl and Arg into the invasive 435s and BT-549 
cells lines, which have endogenously high c-Abl/Arg activity and low NM23-H1 
expression. Knocking down c-Abl or Arg resulted in a significant increase in NM23-H1 
expression (Figure 3.2a,b, left). Furthermore, inhibition of c-Abl and Arg activity with
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Figure 3.1 Abl Kinase Activity and NM23-H1 Expression are Inversely Correlated in 
Cell Lines  
M
B
-4
68
!
M
C
F-
7!
B
T-
47
4!
SK
B
R
3!
M
B
-2
31
!
B
T-
54
9!
43
5s
!
α-tubulin!
NM23-H1!
c-Abl Kinase Assay!
Arg Kinase Assay !
                  NM23-H1:    0.6       1       0.2    0.4    0.3    0.1     0.1       0.5!
 relative to α-tubuli!
Relative c-Abl activity:  1. 1      1         3      0.3      1.9      7      4.1      1.6     !
Relative Arg activity:   4.7     1        1.1   1.6     3.9      10     15       3.3!
W
M
32
48
!
43
5s
!
SB
cl
2!
W
M
27
8!
α-tubulin blot !
W
M
23
9!
A
37
5!
pCrk/CrkL blot!
NM23-H1:       1        6.2      4.1      2.5      1.1     0.5     !
 relative to α-tubulin!
NM23-H1 blot !
pCrk/CrkL:       1       0.8       0.7     0.9     1.3     2.6 !
relative to α-tubulin!
α-tubulin blot !
(for NM23)!
-0.3!
-0.2!
-0.1!
0!
0.1!
0.2!
0.3!
0.4!
0.5!
0! 0.5! 1!
R!
2!
 = 0.7687!
 p= 0.02!
N
M
23
-H
1 
Ex
pr
es
si
on
 [l
og
]!
pCrk/CrkL Expression [log]!
N
M
23
-H
1 
Ex
pr
es
si
on
 [l
og
]!
c-Abl+Arg Activity [log]!
2!
R!  = 0.6264!
-1.2!
-1!
-0.8!
-0.6!
-0.4!
-0.2!
0!
0! 0.2! 0.4! 0.6! 0.8! 1! 1.2! 1.4!
p=0.02!
U
A
C
C
-8
93
!
a b melanoma! breast cancer!
 
Figure 3.1 Abl kinase activity and NM23-H1 expression are inversely correlated in 
cell lines. (a,b) c-Abl/Arg activities were assessed indirectly via phosphorylation of 
substrates, Crk/CrkL  (a) or directly by in vitro kinase assay (b), in melanoma (a) or 
breast cancer (b) cell lines, bands quantitated, and log-transformed values for c-Abl+Arg 
activity plotted against log-transformed NM23-H1 expression values. The inverse 
correlations were statistically significant. (a) Pearson's correlation coefficient =-0.79, 
95% confidence interval -0.96 to -0.19, p=0.02. (b) Pearson's correlation coefficient =-
0.85, 95% confidence interval -0.98 to -0.139, p=0.03.  Panel (a) Performed by W. 
Friend and S. Ganguly and panel (b) performed by R. Plattner and D. Srinivasan. 
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Figure 3.2 c-Abl and Arg Activation Induces Loss of NM23-H1 Expression   
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Figure 3.2 c-Abl and Arg activation induces loss of NM23-H1 expression.  (a,b) Cell 
lines containing highly active c-Abl/Arg were transfected with c-Abl or Arg siRNAs (#1 
and #2 are independent siRNAs) or treated with imatinib (10µM) or nilotinib (5µM) for 8h, 
and NM23-H1 expression examined by western blot. Bands were quantitated, and 
values expressed relative to loading controls and to scrambled- or vehicle-treated cells. 
(c) Western blot analysis of lysates from WM164 melanoma cells transiently transfected 
with constitutively active c-Abl and Arg (PP) (72h). Relative NM23-H1 expression 
(relative to loading control) was graphed (Mean±SEM for 3-4 independent experiments). 
*p<0.05, **p<0.01, ***p<0.001 using one-sample t-tests. R. Plattner performed siRNA #1 
experiment in panel a,b S. Ganguly performed siRNA#2 experiment in panel a,b, and 
experiment in panel c. 
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imatinib or the second generation c-Abl/Arg inhibitor, nilotinib, significantly increased 
NM23-H1 expression (Figure 3.2 a,b, right). Next, we transfected constitutively active c-
Abl-PP and Arg-PP into the non-invasive WM164 melanoma cell line and observed a 
decrease in NM23-H1 expression (Figure 3.2 c). Taken together, these data 
demonstrate that c-Abl and Arg kinases downregulate NM23-H1 expression in a kinase-
dependent manner.  
Abl Family Kinases Do Not Transcriptionally Regulate NM23-H1 
Several studies have linked NM23-H1 mRNA expression to loss of invasive and 
metastatic potential [69, 128], while others have shown the opposite [106, 129] or no 
correlation [115, 130].  Therefore, we investigated if the decrease in NM23-H1 protein 
expression we observed with c-Abl/Arg knockdown/inhibition could be due to mRNA 
regulation. First, to determine if NM23-H1 mRNA and protein levels are correlated in 
melanoma and breast cancer cells, we analyzed NM23-H1 mRNA levels using 
quantitative real-time RT-PCR on melanoma and breast cancer cell lines. We 
determined RPS13 to be the most stable reference gene among the five that we tested 
(β-actin, HSP13, RP2, RPS11, and RPS13) (Figure 3.3a). There was no significant 
correlation between NM23-H1 mRNA and protein levels in melanoma and breast cancer 
cell lines (Figure 3.3 b-d) suggesting that protein levels of NM23-H1 are regulated 
independently of mRNA expression. To confirm that c-Abl and Arg do not regulate 
NM23-H1 mRNA expression, we performed semi-quantitative RT-PCR in 435s cells, and 
observed no change in NM23-H1 mRNA following siRNA-mediated knockdown of c-Abl 
and Arg (Figure 3.3e). Taken together, these results indicate that c-Abl and Arg do not 
regulate NM23-H1 mRNA expression; therefore, c-Abl/Arg downregulation of NM23-H1 
is likely a post-transcriptional mechanism.  
NM23-H1 is Degraded via Lysosomal Cathepsins  
To determine the mechanism in which c-Abl and Arg post-transcriptionally regulate 
NM23-H1, we determined the previously unknown mechanism of NM23-H1 protein 
degradation. Abl family kinases have been shown to promote proteasomal degradation 
[63]; therefore, we investigated if NM23-H1 could be a substrate of the proteasome. 
Treatment with proteasome inhibitors MG132 and Proteasome Inhibitor 1 (PS1) resulted 
in no change in NM23-H1 expression levels regardless of dose or length of treatment, 
whereas proteasomal substrates such as p27 and cyclin D1 were significantly
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Figure 3.3 c-Abl and Arg Do Not Trancriptionally Regulate NM23-H1  
melanoma-RPS13! melanoma-NM23-H1! melanoma-NM23-H1/RPS13!
R
el
at
iv
e 
m
R
N
A 
!
Ex
pr
es
si
on
 (Δ
C
q)
 !
0!
0.5!
1!
1.5!
2!
2.5!
3!
HE
Mn
!
WM
27
8!
WM
23
9!
A3
75
!
SB
cl2
!
WM
32
48
!
43
5s
!
0!
0.5!
1!
1.5!
2!
HE
Mn
!
WM
27
8!
WM
23
9!
A3
75
!
SB
cl2
!
WM
32
48
!
43
5s
!0!
0.5!
1!
1.5!
2!
HE
Mn
!
WM
27
8!
WM
23
9!
A3
75
!
SB
cl2
!
WM
32
48
!
43
5s
!
R
el
at
iv
e 
m
R
N
A 
!
Ex
pr
es
si
on
 (Δ
Δ
C
q)
 !
0!
0.5!
1!
1.5!
2!
2.5!
3!
3.5!
H
M
EC
!
M
D
A
-4
68
!
M
C
F7
!
B
T-
47
4!
SK
B
R
3!
M
D
A
-2
31
!
B
T-
54
9!
43
5s
!
U
A
C
C
!
breast-RPS13! breast-NM23-H1/RPS13!breast-NM23-H1!
0!
0.5!
1!
1.5!
2!
2.5!
3!
3.5!
H
M
EC
!
M
D
A
-4
68
!
M
C
F7
!
B
T-
47
4!
SK
B
R
3!
M
B
-2
31
!
B
T-
54
9!
43
5s
!
U
A
C
C
! 0!
0.5!
1!
1.5!
2!
2.5!
3!
H
M
EC
!
M
D
A
-4
68
!
M
C
F-
7!
B
T-
47
4!
SK
B
R
3!
M
B
-2
31
!
B
T-
54
9!
43
5s
!
U
A
C
C
!
R
el
at
iv
e 
m
R
N
A 
!
Ex
pr
es
si
on
 (Δ
C
q)
 !
R
el
at
iv
e 
m
R
N
A 
!
Ex
pr
es
si
on
 (Δ
Δ
C
q)
 !
breast cancer lines!melanoma cell lines!
R
el
at
iv
e 
N
M
23
-H
1 
!
Pr
ot
ei
n 
Ex
pr
es
si
on
!
y = -0.0308x + 0.4453!
R² = 0.00282!
0!
0.2!
0.4!
0.6!
0.8!
1!
1.2!
0! 1! 2! 3!
 p= 0.9!
y = 0.7222x + 1.7642!
R² = 0.01402!
0!
1!
2!
3!
4!
5!
6!
7!
0! 1! 2!
 p= 0.82!
NM23-H1/RPS13 (ΔΔCq) !
siRNA:  Scr   Abl     Arg!
NM23-H1!
β-actin!
R
el
at
iv
e 
N
M
23
-H
1 
m
R
N
A 
!
(N
M
23
/β
-a
ct
in
)!
0!
0.5!
1!
Scr! Abl! Arg!siRNA:!
a 
b 
0!
0.2!
0.4!
0.6!
0.8!
1!
1.2!
1.4!
1.6!
1.8!
 β-Actin! HSP13! RP2! RPS11! RPS13!
HEMn! WM278! WM239!
A375! SBcl2! WM3248!
435s!
0!
0.5!
1!
1.5!
2!
2.5!
 β-Actin! HSP13! RP2! RPS11! RPS13!
HMEC! MDA-468! MCF7!
BT-474! SKBR3! MB-231!
MCF7! BT-549! UACC!
c 
d e 
melanoma! breast!
R
el
at
iv
e 
m
R
N
A 
Ex
pr
es
si
on
 (Δ
C
q)
 !
R
el
at
iv
e 
m
R
N
A 
Ex
pr
es
si
on
 (Δ
C
q)
 !
 55 
Figure 3.3 c-Abl and Arg do not transcriptionally regulate NM23-H1. (a-c) mRNA 
levels of were quantitated by real-time RT-qPCR (a) loading controls in a panel of 
serum-starved melanoma (left) or breast cancer (right) cell lines (b,c) Graphs are panel 
of serum-starved melanoma (b) or breast cancer (c) cell lines. Mean±SEM for 2 
independent experiments performed in duplicate. Reference (RPS13), NM23-H1 (non-
normalized), and NM23-H1 relative to RPS13 are shown. NM23-H1 protein is above 
graphs. HMEC=human mammary epithelial cells. HEMn=human epidermal melanocytes 
(light pigment). (d) NM23-H1 mRNA was graphed relative to protein for all cancer lines 
(excludes non-cancer cells). (e) cDNA was prepared from RNA from 435s cells 
expressing c-Abl or Arg siRNAs, and subjected to semi-quantitative RT-PCR using 
NM23-H1 primers and internal control b-actin primers. Relative NM23-H1 expression 
(relative to loading control) was graphed (Mean±SEM for 3 independent experiments). 
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upregulated (Figure 3.4a,b).  These results indicate c-Abl and Arg downregulate NM23-
H1 in a proteasome-independent manner.  
Next, we investigated if NM23-H1 degradation occurred via the lysosome, a 
protease-filled organelle involved in protein turnover. Inhibition of the lysosome with 
ammonium chloride (NH4Cl) or chloroquine in 435s and BT-549 cells increased NM23-
H1 expression levels, suggesting lysosomal involvement in NM23-H1 degradation 
(Figure 3.5a,b). Within the lysosome, cathepsin proteases are responsible for the 
degradation of proteins. To determine the specific proteases responsible for NM23-H1 
degradation, we treated 435s and BT-549 cells with a cell-permeable cysteine protease 
inhibitor, E64d, and observed increased NM23-H1 expression (Figure 3.5 a,b). Of the 11 
cysteine proteases, cathepsins L and B are the most documented in promoting invasion 
and metastasis [37, 41]; therefore, we hypothesized they may be responsible for 
degrading a metastasis suppressor. Indeed, siRNA-mediated knockdown of cathepsins 
L and B significantly increased NM23-H1 expression in both 435s and BT-549 cells 
(Figure 3.5c). Furthermore, using an in vitro cleavage assay, we demonstrated that 
cathepsins L and B directly cleave NM23-H1 [89]. These data indicate that lysosomal 
cathepsins L and B are responsible for the degradation of NM23-H1.  
Abl Family Kinases Increase Cathepsin L/B Expression and Activation 
 We demonstrated that c-Abl/Arg and cathepsins L/B are both involved in the 
downregulation of NM23-H1; therefore, we investigated if c-Abl and Arg affect cathepsin 
L and B activation and/or expression. Cathepsins are expressed as proforms in the golgi 
apparatus and early endosomes, then cleaved to an intermediate active form in the late 
endosome, and subsequently cleaved again to a double chain active form within the 
lysosome [37]. Inhibition of c-Abl/Arg with imatinib or nilotinib in 435s cells, resulted in 
decreased double-chain active cathepsin L/B and increased procathepsin L/B 
(Figure3.6a, left), indicating that c-Abl/Arg activity promote the cleavage of cathepsin L 
and B to their double-chain mature form in melanoma cells. In BT-549 cells, we also 
observed the cleavage of cathepsin L to be blocked following c-Abl/Arg inhibition; 
however, very little double chain active form is present in these cells, thus, we observed 
a reduction in the cleavage of the pro-form to the single chain active form instead (Figure 
3.6b, left). These data demonstrate that c-Abl/Arg promote cleavage of cathepsins L/B to 
their active forms.   
Next, we investigated the effects of siRNA-mediated knockdown of c-Abl and Arg 
on cathepsin L and B expression/activation. In 435s cells, we observed decreased 
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Figure 3.4 NM23-H1 is Not a Proteasomal Substrate  
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Figure 3.4 NM23-H1 is not a proteasomal substrate. (a,b) Lysates from 435s (a) and 
BT-549 (b) detached and attached cells treated with the proteasome inhibitor, MG132 
and proteasome inhibitor 1 (PS1)  and probed with antibodies. Relative NM23-H1 
expression (relative to loading control) was graphed with mean ±SEM for three 
independent experiments. p<0.05, **p<0.01, ***p<0.001 using one-sample t-tests.  
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Figure 3.5  NM23-H1 is Degraded by Lysosomal Cysteine Proteases, Cathepsins L 
and B 
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Figure 3.5  NM23-H1 is degraded by lysosomal cysteine proteases, cathepsins L 
and B. (a,b) Western blot analysis of lysates from cells treated with lysosomal inhibitors 
(ammonium chloride, 20mM (BT-549) or 60mM (435s, BT-549); chloroquine, 100mM) or 
the cysteine protease inhibitor, E64d (20mM) for 8h. (c) Lysates from cell lines 
transfected with siRNAs were blotted with antibodies 72h after the initial transfection. 
Relative NM23-H1 expression (relative to loading control) was graphed  with the 
mean±SEM for 3 independent experiments. *p<0.05, **p<0.01, ***p<0.001 using one-
sample t-tests.  
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Figure 3.6 c-Abl and Arg Promote Cathepsin Expression and Activation 
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Figure 3.6 c-Abl and Arg promote cathepsin expression and activation. (a,b) 
Western blot analysis of lysates from 435s (a) and BT-549 (b) cells treated with imatinib 
(10µM) or nilotinib(5µM) for 48h (left) or transfected with siRNAs (right), and replated 
24h prior to lysis such that densities were equivalent. Relative cathepsin expression 
levels (relative to loading control) were graphed  with the mean±SEM for 3 independent 
experiments. *p<0.05, **p<0.01, ***p<0.001 using one-sample t-tests.  p=procathepsin, 
i=intermediate, d-double chain. siRNA experiment in panel (a) performed by S. Ganguly. 
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expression of the double-chain active form of cathepsins L/B following c-Abl knockdown; 
however, no significant change was observed with Arg knockdown, indicating that 
cathepsin activation is c-Abl-dependent in these cells (Figure 3.6a, right). Interestingly, in 
contrast to the increase in the proform of cathepsins L/B we observed with imatinib and 
nilotinib, silencing c-Abl and Arg in 435s cells decreased procathepsin expression, 
suggesting c-Abl and Arg upregulate cathepsin expression in a kinase-independent 
manner (Figure 3.6a, right). In BT-549 cells, silencing c-Abl and Arg decreased the 
double chain active form of cathepsin L, however the cathepsin B active form only 
decreased with Arg knockdown, indicating that activation of cathepsin B in BT-549 cells 
is an Arg-dependent mechanism (Figure 3.6b, right). Furthermore, similar to 435s, 
silencing c-Abl and Arg decreased the procathepsin form of both cathepsins L and B in 
BT-549 cells. In summary, in 435s cells, activation of cathepsin L and B is c-Abl-
dependent, whereas in BT-549 cells it is Arg-dependent. Furthermore, c-Abl and Arg 
increase the expression of the proform of cathepsins L and B; however c-Abl/Arg kinase 
activity has no effect on proform expression, indicating that c-Abl and Arg upregulate 
cathepsins L and B expression in a kinase-independent manner.   
 Our observation that c-Abl and Arg increase expression of procathepsin L and B 
led us to investigate if c-Abl and Arg regulate cathepsin L/B mRNA levels. In the 435s 
cells, knockdown of both c-Abl and Arg reduced cathepsin L and B mRNA levels, and 
Arg knockdown had the most dramatic effect (Figure 3.7a). In BT-549 cells, cathepsin L 
mRNA levels were decreased following c-Abl but not Arg knockdown. Interestingly, in 
BT-549 cells, neither c-Abl nor Arg knockdown had an effect on cathepsin B mRNA 
levels (Figure 3.7b). Our data demonstrating that procathepsin L and B proteins are not 
reduced following nilotinib treatment is further supported by data demonstrating that 
nilotinib had no effect on cathepsin L/B mRNA levels (Figure 3.7a,b). In summary, c-Abl 
and Arg promote activation of cathepsin L and B in a kinase-dependent manner, 
whereas c-Abl and Arg promote expression of cathepsin L/B mRNA in a kinase-
independent manner. 
Abl Family Kinases Promote Endosomal Trafficking of NM23-H1 to the Lysosome 
We demonstrated that inhibition of c-Abl/Arg increased expression of the early 
endosome form of cathepsin L/B and decreased expression of the lysosomal forms, 
suggesting that c-Abl and Arg may play a role in endosomal vesicular trafficking. To 
determine if c-Abl/Arg activity promotes endosomal trafficking and delivery of NM23-H1 
to the lysosome, we treated 435s cells with nilotinib and performed a Percoll-gradient
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Figure 3.7  c-Abl and Arg Promote Cathepsin Expression in a Kinase-Independent 
Manner 
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Figure 3.7  c-Abl and Arg promote cathepsin expression in a kinase-independent 
manner. (a,b) Cathepsin mRNA levels in cells treated with nilotinib (5µM, 48h) or 
transfected with siRNAs (72h) were examined by semi-quantitative RT-PCR. Knockdown 
efficiency is shown (right). pCrk/CrkL (c-Abl/Arg targets) blots indicate that nilotinib 
effectively inhibited c-Abl/Arg. Relative cathepsin mRNA expression levels (relative to 
loading control) were graphed with the mean±SEM for 3 independent experiments. 
*p<0.05, **p<0.01 using one-sample t-tests.  
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subcellular fractionation. In vehicle-treated cells, lysosomes (LAMP1=lysosome marker) 
and late endosomes (Rab7) were localized within high-density fractions (fractions 10-
12), and the early endosomes (EEA1) were localized within low-density fractions 
(fractions 1-6) and high-density fractions (fractions 10-12) (Figure 3.8a, left). We believe 
that EEA1 localization in high-density fractions is due to the formation of hybrid vesicles 
as early endosomes mature to a late endosomes. In vehicle-treated cells, NM23-H1 
localized in all fractions; however, expression was higher in the early endosome 
fractions as compared to the lysosome fractions, likely due to degradation of NM23-H1 
within the lysosome (Figure 3.8a, left). Inhibition of c-Abl/Arg with nilotinib resulted in 
increased early endosomes (Figure 3.8a,b), decreased lysosomes (Figure 3.8a, c), and 
a slight decrease in late endosomes (Figure 3.8a, d). Furthermore, c-Abl/Arg inhibition 
increased NM23-H1 expression within endosomal fractions coupled with decreased 
expression in the lysosomal fractions (Figure 3.8a, e-h). Taken together, these results 
demonstrate that c-Abl/Arg activity induces NM23-H1 degradation via promoting 
endosomal trafficking to the lysosome.  
Abl Family Kinases Promote Invasion/Metastasis via NM23-H1 Downregulation 
Previously, our lab demonstrated that c-Abl and Arg kinases promote invasion in 
435s and BT-549 cells [56, 89]. Therefore, we investigated if c-Abl and Arg promote 
invasion in these cells by inducing NM23-H1 degradation. Inhibition of c-Abl/Arg 
increased NM23-H1 expression and inhibited invasion in 435s and BT-549 cells (Figure 
3.9a,b). However, preventing the upregulation of NM23-H1 by silencing NM23-H1 with 
an shRNA, partially rescued the block in invasion we observed in nilotinib-treated cells 
(Figure 3.9a,b), indicating c-Abl and Arg promote invasion by degrading NM23-H1. 
Since c-Abl/Arg promote invasion by downregulating NM23-H1, we hypothesized 
that downregulation of NM23-H1 also was required for c-Abl/Arg to promote metastasis. 
Green fluorescent protein (GFP)/luciferase-labeled 435s cells were injected into the tail 
vein of SCID-beige mice. Metastatic burden was measured by IVIS imaging. Mice 
treated with nilotinib had significantly decreased metastatic burden as compared to mice 
treated with vehicle (Figure 3.10a,b). To determine if the outlier (mouse #10) with large 
metastases in the nilotinib-treated group responded to nilotinib treatment, we sectioned 
the lungs and performed immunohistochemistry assessing c-Abl/Arg activity by staining 
with antibody to the phosphorylated c-Abl/Arg substrate, Crk/CrkL. We observed intense 
pCrk/CrkL staining in the lung metastases from mouse #10 as compared to mouse #9 
with low metastatic burden and low pCrk/CrkL staining (Figure 3.10c, left), indicating that 
 66 
 
Figure 3.8  c-Abl and Arg Kinase Activity Promotes Endosome-Lysosome 
Trafficking and Promotes NM23-H1 Expression in Lysosomal Fractions 
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Figure 3.8  c-Abl and Arg kinase activity promotes endosome-lysosome trafficking 
and promotes NM23-H1 expression in lysosomal fractions. (a) 435s cells, treated 
with vehicle/nilotinib (5µM, 8h), were subjected to 20% Percoll gradient fractionation. 
Twelve fractions were collected, the indicated fractions (1,3,4,6,8,9-12) from vehicle- and 
nilotinib-treated cells were run on the same gel, and blotted with EEA1, Rab7 or LAMP-1 
antibodies (top). Since all 24 fractions could not be run on one gel and fractions 2,5,7 
were missing from the first gel, consecutive vehicle- and nilotinib-treated endosomal 
fractions (1-8) were rerun on a second gel. Western blots from one of three experiments 
are shown. Two independent experiments are shown for NM23-H1. (b-h) Bands were 
quantified and graphed. (c) Mean±SEM, n=2 for fractions 10-12 blotted with LAMP1 
antibody. (h) Mean±SEM, n=2 for fractions 8-12 blotted with NM23-H1 antibody.
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Figure 3.9. c-Abl/Arg Promote Invasion by Inducing NM23-H1 Loss 
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Figure 3.9. c-Abl/Arg promote invasion by inducing NM23-H1 loss. (a,b) 435s (a) or 
BT-549 (b) cells expressing non-targeting vector (PLK01) or NM23-H1 shRNA were 
serum-starved and treated with imatinib for 8h (435s; 10µM) or 16h (BT-549; 5µM), and 
utilized in a matrigel invasion assay. Lysates from a representative experiments were 
probed with antibodies. Brackets indicate comparisons among groups (***p<0.001), 
whereas dotted lines indicate post-hoc pairwise comparisons (*p<0.05, **p<0.01, or n.s. 
non-significant). S. Ganguly performed invasion assay experiments. 
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Figure 3.10. c-Abl/Arg Promote Metastasis by Inducing NM23-H1 Loss 
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Figure 3.10. c-Abl/Arg promote metastasis by inducing NM23-H1 loss. (a,b) [57] 
SCID-beige mice were injected with 435s cells expressing GFP/luciferase and treated 
with nilotinib (n=7) by oral gavage and imaged with IVIS. (a) IVIS imaging of mice on 
days 17, 21, and 24. (b) quantitated fluorescence of mice on day 21. Each data point 
represents an animal and numbers correlate to numbers in panel a. **0.001≤p<0.01. (c) 
Lungs from nilotinib-treated mice were taken on day 24 and stained with normal rabbit 
serum or antibody directed against phosphorylated Crk/CrkL, and visualized with DAB. 
IVIS fluorescent values plotted against pCrk/CrkL IHC intensity scores (1-3+) in 
metastases (right). A positive correlation was observed between the values (R2=0.72, 
p=0.008). (d,e) Lungs from nilotinib-treated mice were stained with NM23-H1 or 
pCrk/CrkL antibodies. Representative lungs from responding (low IVIS luminescence; 
mouse #6) and non-responding (high IVIS luminescence; mouse #10) mice are shown 
(d). NM23-H1 IHC scores were plotted against IVIS flux (left) or pCrk/CrkL scores (right) 
(e). NM23-H1/Flux Pearson's correlation coefficient = 0.92, 95% confidence interval -
0.988 to -0.544, p=0.0033. NM23-H1/pCrk/CrkL Pearson's correlation coefficient =0.78, 
95% confidence interval -0.965 to -0.068, p=0.038.  Metastasis assays (a,b) performed 
by S. Ganguly.  
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c-Abl/Arg activity was not inhibited in response to nilotinib treatment in this mouse. In 
fact, pCrk/CrkL staining was positively correlated with metastatic burden in all mice, 
demonstrating that c-Abl/Arg kinase activity promotes metastasis (Figure 3.10c, right). 
Next, we investigated if c-Abl/Arg require the downregulation of NM23-H1 to promote 
metastasis. In addition to pCrk/CrkL staining, we stained serial lung sections with 
antibody to NM23-H1. Mouse #10, which had high metastatic burden and intense 
pCrk/CrkL staining, stained weakly for NM23-H1 as compared to mouse #6 with low 
metastatic burden, low pCrk/CrkL staining, staining intensely for NM23-H1 (Figure 3.10d, 
left). Furthermore, NM23-H1 expression was significantly inversely correlated to 
metastatic burden and pCrk/CrkL staining (Figure 3.10e), revealing that inhibition of c-
Abl/Arg increases NM23-H1 expression preventing metastasis. In conclusion, c-Abl/Arg 
require the downregulation of NM23-H1 to promote invasion and metastasis.  
c-Abl/Arg Activity and NM23-H1 Expression are Inversely Correlated in Melanoma and 
Breast Cancer and Primary Tissue 
 To determine if the downregulation of NM23-H1 via c-Abl/Arg that we observe in 
cell lines and in mice also occurs in human tissue, we stained melanoma and breast 
cancer tissue microarrays with pCrk/CrkL and NM23-H1 antibody to assess c-Abl/Arg 
activity and NM23-H1 expression. Melanoma and breast cancers that stained intensely 
with pCrk/CrkL antibody had low expression of NM23-H1, and vice versa (Figure 3.11a,b 
left). In fact, there was a significant inverse correlation between pCrk/CrkL staining and 
NM23-H1 expression (Figure 3.11a,b right), confirming that the mechanism of c-Abl/Arg 
downregulation of NM23-H1 expression observed in human cell lines and in vivo also 
exists in human melanoma and breast cancer primary tissues.  
Discussion 
 
Here, we demonstrate a novel pathway in which the oncogenic Abl family 
kinases promote invasion and metastasis via cathepsin-mediated degradation of the 
NM23-H1 metastasis suppressor. Prior to our studies, very little was known regarding 
upstream regulators of NM23-H1 and the mechanism of NM23-H1 protein turnover also 
was unknown. We reveal a mechanism by which NM23-H1 is degraded within the 
lysosome via cathepsins L and B. Cathepsin involvement in invasion and metastasis 
often focuses on cathepsin-mediated extracellular matrix degradation; therefore, the 
discovery that cathepsins degrade a metastasis suppressor within the lysosome reveals
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Figure 3.11. c-Abl/Arg Activation is Inversely Correlated with NM23-H1 Expression 
in Primary Melanomas and Breast Cancers 
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Figure 3.11. c-Abl/Arg activation is inversely correlated with NM23-H1 expression 
in primary melanomas and breast cancers. (a) Melanoma TMAs containing benign 
nevi (n=18), primary melanomas (n=48), and melanoma metastases (n=19) (ME1003) 
were stained with pCrk/CrkL, NM23-H1 (D98), or IgG antibodies; and scored by a 
pathologist. Representative cores are on left.  Cores were grouped into low (≤0.5), 
medium (1-2.5) and high (>2.5) NM23 intensity of stain and pCrk/CrkL intensity of stain, 
and the percentage of cases containing low, medium, or high NM23-H1 staining in each 
pCrk/CrkL group was graphed (right). An inverse correlation was observed: p=0.016 with 
a Fisher’s Exact test-3X3 and Kendall's tau-b=-0.2637, 95% CI -0.4540 to -0.0734, 
p=0.009.  (b) Breast cancer TMA serial sections (BR10010a; n=100), were stained with 
pCrk/CrkL and NM23-H1 antibodies and scored by a pathologist (Michael Cibull, M.D.). 
Score = intensity * percentage of tumor.  pCrk/CrkL scores were grouped into negative 
(0), Low (.1-.5), Medium (.6-1.6), and High (1.7-3). NM23-H1 scores were grouped into 
Low (>1), Medium (1-1.9) and High (>1.9). An inverse correlation between pCrk/CrkL 
and NM23-H1 was observed (p=0.032; Kendall’s tau-b = -0.177 with 95% confidence 
interval -0.339 to -0.015). IgG controls shown (top).  
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a novel role for cathepsins as intracellular regulators of metastasis in addition to their 
extracellular functions. Furthermore, we demonstrate that c-Abl and Arg promote 
cathepsin-mediated NM23-H1 degradation revealing a novel mechanism in which an 
oncogene downregulates a metastasis suppressor to promote invasion and metastasis 
(Figure 3.12).  
 Inhibition of c-Abl/Arg resulted in increased expression of procathepsin L/B 
coupled with decreased active cathepsin L/B. Additionally, we observed an accumulation 
of endosomes and a decrease in lysosomes following c-Abl/Arg inhibition, indicating that 
c-Abl/Arg promote endosomal trafficking to the lysosome. The switch from Rab5 
GTPase expression on the early endosome membrane to Rab7 GTPase on the late 
endosome membrane is an essential step for maturation of endosomes to lysosomes. 
One potential mechanism by which the Abl family kinases may promote endosome 
maturation is through the Rab5/Rab7 switch. PI3K activation leads to an accumulation of 
PI(3)P within the vesicle membrane promoting the recruitment of a Rab7-GEF, which 
then subsequently recruits the Rab7 GTPase [30]. Abl oncogene variants with enhanced 
kinase activity such as v-Abl (fusion product of Mo-MuLV gag and truncated c-Abl) [131] 
and BCR/Abl (fusion product of BCR and truncated c-Abl) [49] have been reported to 
bind and activate PI3K in NIH3T3 fibroblasts [132], whereas endogenous c-Abl does not 
activate PI3K [132]. However, basal c-Abl activity in NIH3T3 fibroblasts is not 
constitutively active unlike v-Abl and BCR/Abl. Our lab has demonstrated that melanoma 
and breast cancer cells such as 435s and BT-549 cells have high c-Abl and Arg activity 
[56]; therefore, in these cancer cells c-Abl may activate PI3K in similar manner to v-Abl 
and BCR/Abl in fibroblasts. Our laboratory has reported that inhibition of c-Abl/Arg had 
no effect on the phosphorylation of Akt (a downstream effector of PI3K) [61]; however, 
the PI3K/AKT/mTOR pathway is associated with class I PI3K [133], whereas endosomal 
trafficking is associated with class III PI3K [134]. Therefore, we hypothesize that c-
Abl/Arg activate Class III PI3K leading to the accumulation of PI(3)P at the endosomal 
membrane promoting the Rab5/Rab7 switch and endosome maturation. 
 Interestingly, Plattner et al. demonstrated that c-Abl and Arg have the ability to 
bind to PI(3)P [135]. Therefore, we can form an alternative hypothesis that rather than c-
Abl/Arg promoting the accumulation of PI(3)P, PI(3)P may recruit c-Abl and Arg to the 
endosomal membrane. Recruitment of c-Abl and Arg to the endosomal membrane could 
potentially promote actin reorganization, which is also necessary for the Rab5/Rab7 
switch and endosome maturation [23]. Nucleation promoting factors (NPF) interact with
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Figure 3.12 Effect of c-Abl on Endocytic Trafficking 
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Figure 3.12 Effect of c-Abl on endocytic trafficking. Model for the mechanism by 
which c-Abl/Arg promote vesicular trafficking and NM23-H1 degradation. c-Abl and Arg 
promote expression of cysteine cathepsins B, L by increasing mRNA levels and c-Abl 
induces cathepsin activation by promoting endosome->lysosome trafficking. Endosomal 
NM23-H1 is transported to lysosomes and degraded by lysosomal cathepsins B,L. 
Inhibition or silencing c-Abl/Arg prevents cathepsin expression and activation, which 
leads to stabilization of NM23-H1. MT=microtubules, MVB=multi-vesicular body. 
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the actin-related protein, ARP2/3, to nucleate branched actin filament networks [36]. The 
WASH NPF is specific for actin reorganization involved with endosomal trafficking [36]. 
c-Abl/Arg have been found to phosphorylate several NPFs including N-Wasp, WAVE2, 
WAVE3 and Cortactin [136-139]. Given that c-Abl/Arg phosphorylate several NPFs, they 
conceivably could have a role in phosphorylating the WASH NPF and thus activate 
ARP2/3. thereby promoting endosomal trafficking. Additionally, it is possible that c-
Abl/Arg phosphorylation of N-Wasp, WAVE2, WAVE3, or cortactin may also promote 
endosomal trafficking.  
 Cathepsins L and B are commonly over-expressed in aggressive cancers [140].  
Here, we demonstrate a novel mechanism in which c-Abl and Arg increase cathepsin 
L/B mRNA and protein expression. Knockdown of c-Abl and Arg with siRNA resulted in 
decreased cathepsin L/B mRNA and protein expression whereas kinase inhibition with 
nilotinib had no effect indicating that c-Abl and Arg increase cathepsin L/B expression in 
a kinase-independent manner. The STAT3 transcription factor has been reported to 
have a role in promoting cathepsin L and B transcription [141] and our laboratory 
demonstrated that c-Abl/Arg promote STAT3 activation [61]. However, c-Abl/Arg activate 
STAT3 via an indirect, kinase-dependent mechanism [57], whereas the effect of c-
Abl/Arg on cathepsin mRNA levels is kinase-independent. The presence of SH2 and 
SH3 binding domains within c-Abl and Arg may allow for kinase-independent scaffolding 
functions. Therefore, we propose c-Abl and Arg may have an additional indirect, kinase-
independent role as a regulator of STAT3. c-Abl and Arg have been reported to be 
involved in protein turnover  by promoting the ubiquitination and degradation of proteins. 
c-Abl and Arg often promote ubiquitination in a kinase-dependent manner [62, 142, 143]; 
however, c-Abl has also been demonstrated to have a kinase-independent function in 
ubiquitination and degradation. c-Abl binds and promotes the ubiquitination of the DNA 
binding protein, DDB2 (DNA damage-binding protein 2)  [63]. This mechanism is 
mediated through the CUL4 E3 ligase complex. Interestingly, c-Abl kinase activity was 
not required for c-Abl-dependent ubiquitination and degradation of DDB2 via CUL4. [63]. 
Therefore, we hypothesize that independent of their kinase activity, c-Abl/Arg promote 
the ubiquitination and subsequent degradation of a protein inhibitor of activated STAT3, 
PIAS, which inhibits STAT3 DNA-binding activity [144].  c-Abl/Arg degradation of PIAS in 
a kinase-independent manner would allow for activation of STAT3 and upregulation of 
cathepsin L/B mRNA expression.  
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 The attenuation of invasion that we observe in cells with c-Abl/Arg knockdown or 
inhibition was rescued with stable knockdown of NM23-H1, demonstrating that c-Abl and 
Arg require the downregulation of NM23-H1 to promote invasion in melanoma and 
breast cancer cells. Furthermore, we also observed that c-Abl/Arg inhibition increased 
NM23-H1 expression levels within early endosomal fractions, suggesting that the build 
up of NM23-H1 within the endosomes suppresses invasion. Receptor tyrosine kinases 
(RTK), which are endocytosed and sequestered within the endosomal compartments, 
often maintain their signaling capabilities [145]; therefore it is conceivable that the 
metastatic suppressing functions of NM23-H1 may remain intact within the endosome 
compartment. In fact, NM23-H1 is involved in regulating endocytosis. The Drosophila 
homolog of NM23, awd, increased the efficiency of dynamin, a GTPase with an essential 
role in endocytosis [146], indicating that NM23-H1 promotes endocytosis. Furthermore, 
in human MDCK cells, ARF6, which can localize to the plasma membrane and the 
endosome, recruits NM23-H1, inducing dynamin-dependent vesicle fission/endocytosis 
[77]. Given that c-Abl/Arg inhibition causes NM23-H1 accumulation within the early 
endosome and NM23-H1 promotes endocytosis, we hypothesize that inhibition of c-
Abl/Arg attenuates invasion via ARF6 interacting with NM23-H1 and promoting the 
endocytosis of receptor tyrosine kinases (RTK). Since inhibition of c-Abl/Arg blocks 
maturation of the early endosome to the late endosome, RTKs would remain 
sequestered within the early endosome. Sequestering an RTK such as EGFR within the 
endosome would prevent cell surface mechanisms such as heterodimer formation and 
activation of phospholipase (PLC)-γ, thus decreasing migration.  
ARF6 recruitment of NM23-H1 was also demonstrated to promote the function of 
NM23-H1 as a suppressor of the Rac1 GEF, Tiam1 [75, 77]. Rac1-GTP promotes 
membrane ruffling, invasion and metastasis [147]. ARF6 regulates the movement of 
Rac1 between the plasma membrane and the endosomal compartment [147]. We 
propose that increased levels of NM23-H1 within the endosome increases ARF6 bound 
to NM23-H1. This interaction promotes NM23-H1 inhibition of TIAM1 subsequently 
inhibiting Rac1 and thus inhibiting invasion. In fact, Rac was demonstrated to be 
activated downstream of Abl [148], therefore c-Abl/Arg promoting endosomal trafficking 
may prevent ARF6 recruitment of NM23-H1 subsequently activating TIAM1 and Rac1 
promoting invasion and metastasis.  
Another possible mechanism by which NM23-H1 may mediate metastatic 
suppression within the endosome is via inhibition of TGFβ signaling. The downstream 
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effects of TGFβ are dependent upon cell type and environment. In advanced cancer 
cells, TGFβ signaling promotes epithelial to mesenchymal transition (EMT) and 
metastasis [149]. Activated TGFβ receptors are internalized from the plasma membrane 
and localized to early endosomes [149]. NM23-H1 interaction with the TGFβ negative 
regulator, STRAP, was demonstrated to enhance negative regulation on the TGFβ 
signaling pathway [150]. Therefore, we speculate that increased expression of NM23-H1 
within the endosome following c-Abl/Arg inhibition may promote the interaction of NM23-
H1 and STRAP attenuating TGFβ signaling and thus invasion/metastasis. Finally, one 
may speculate that NM23-H1 localized within the endosome may reduce invasion via the 
phosphorylation and inhibition of the ERK inhibitor, Kinase Suppressor of Ras (KSR), 
given that KSR can localize within the endosome and is a known substrate of NM23-H1 
[151, 152]. However, our laboratory observed c-Abl/Arg inhibition actually increased 
phosphorylation of ERK1/2 in 435s cells, suggesting that NM23-H1 is unlikely acting via 
KSR to suppress invasion following c-Abl/Arg inhibition in this cell type [61, 153].  
Decreased invasion in cells with c-Abl/Arg knockdown/inhibition was only partially 
rescued with stable knockdown of NM23-H1, suggesting that c-Abl/Arg promote invasion 
via multiple pathways. Previously, our lab demonstrated that c-Abl/Arg increase the 
active forms of the proteases, MMP1 and MMP3 [57]. MMPs promote 
invasion/metastasis via degradation of the extracellular matrix. Interestingly, invasion 
was only partially rescued with recombinant MMP1 and MMP3 in c-Abl and Arg 
knockdown cells [57]. Thus, c-Abl and Arg promote invasion via NM23-H1 degradation 
and MMP1 and MMP3 activation. In fact, cathepsins L and B have been reported to 
cleave and activate MMP1 and MMP3 [40], suggesting that c-Abl/Arg may activate 
MMP1 and MMP3 via cathepsin activation. Additionally, increased cathepsin expression 
in cancer cells induces their secretion into the extracellular environment where they 
degrade the extracellular matrix [37]. Therefore, a c-Abl/Arg-dependent increase in  
cathepsin L/B expression/activation likely promotes invasion via three pathways: 
downregulation of the metastasis suppressor NM23-H1, activation of MMP1 and MMP3, 
and cathepsin-mediated degradation of the extracellular matrix (Discussed in Chapter 4).  
Here, we present a novel pathway in which c-Abl/Arg kinases downregulate the 
expression of the metastasis suppressor NM23-H1 in two cell lines, in vivo, and in 
human primary tumors. Identification of agents that can induce the upregulation of 
NM23-H1 in tumors could decrease metastasis and increase patient survival. These 
data demonstrate that treatment of melanoma and triple-negative breast cancers with an 
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inhibitor of c-Abl/Arg such as imatinib or nilotinib may reduce metastasis and increase 
survival of melanoma and breast cancer patients by inducing the re-expression of NM23-
H1. 
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Chapter 4: Discussion and Future Directions  
Summary 
 Our laboratory previously demonstrated that c-Abl and Arg are highly activated in 
melanoma and breast cancer cells and promote proliferation, anchorage-independent 
growth, migration, invasion and metastasis [56, 57, 61]. In Chapter 2, we demonstrated 
that activated c-Abl and Arg are relevant to human disease. In human tissue, we 
reported high c-Abl/Arg kinase activity in melanomas as compared to benign nevi and 
there was a trend towards a positive correlation between c-Abl/Arg activity and early-
onset and intermittently sun-exposed melanomas. Additionally, in human breast cancer 
tissue, c-Abl/Arg activity correlated positively with high-grade tumors. Furthermore, we 
reported that triple-negative tumors have high c-Abl/Arg activity as compared to 
HER2/ER/PR+ tumors and these data will likely reach significance with increased sample 
numbers. Taken together with our previously published in vitro and in vivo data 
demonstrating a role for c-Abl/Arg in melanoma progression [57], these data provide 
clinical evidence that c-Abl and Arg may be novel therapeutic targets in melanomas and 
breast cancers. 
Overexpressed cathepsins in cancer increase invasion and metastasis due to the 
excess cathepsins being secreted into the extracellular environment, where they 
degrade the extracellular matrix (ECM) and activate other proteases (MMPs, uPa) 
involved in ECM degradation [37, 40]. The extracellular role of the cathepsins has been 
well documented; however, little was known regarding how intracellular cathepsins affect 
metastasis. In Chapter 3, we discovered a novel, pro-metastatic, intracellular role for 
these cathepsins demonstrating that the oncogenes, c-Abl and Arg, mediate 
overexpression and activation of cathepsins L and B, subsequently promoting the 
intracellular degradation of the metastasis suppressor, NM23-H1, within the lysosome. 
Additionally, we demonstrated that c-Abl/Arg promote the trafficking of the 
endosome/lysosome pathway to induce cathepsin-mediated NM23-H1 degradation. This 
was the first report of an oncogene downregulating a metastasis suppressor and the first 
reported mechanism for NM23-H1 protein turnover. We also demonstrated clinical 
relevance for this pathway as we observed a significant negative correlation between c-
Abl/Arg kinase activity and NM23-H1 expression in human melanoma and breast cancer 
tissue. Therefore, inhibition of c-Abl and Arg kinases in melanoma and breast cancer 
tumors is likely to elevate expression of NM23-H1, thus decreasing the incidence of 
metastasis, which may increase survival. 
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Future Directions  
 Future directions for this project will focus on elucidating the mechanisms for c-
Abl/Arg promoting endosome maturation and cathepsin mRNA upregulation. We 
demonstrated that c-Abl and Arg activity are required for the maturation of early 
endosomes to late endosomes and lysosomes. An essential step in endosome 
maturation is the switch from Rab5 GTPase expression on the early endosome 
membrane to Rab7 GTPase expression on the late endosome membrane [30]. Within 
the endosomal membrane, PI(3)P accumulation induced by Class III PI3K activation is 
necessary for the recruitment of the Rab7 GEF, which recruits the Rab7 GTPase [30]. 
As mentioned in the discussion for Chapter 3, we hypothesized that c-Abl and Arg 
promote endosome maturation by activating class III PI3K thus causing an accumulation 
of PI(3)P and subsequently inducing the Rab5/Rab7 switch. To test this hypothesis, we 
will utilize a PI3K kinase activity assay to determine if silencing or inhibiting c-Abl and 
Arg reduces class III PI3K activity. If we determine that c-Abl and Arg regulate class III 
PI3K activity, we will investigate if this activation promotes endosome maturation. We 
demonstrated that c-Abl/Arg promote the maturation of early endosomes to lysosomes 
by performing a Percoll-gradient fractionation following inhibition of c-Abl and Arg and 
we observed an accumulation of early endosomes and a decrease in lysosomes with c-
Abl/Arg inhibition as compared to vehicle treatment (Chapter 3). To test if c-Abl and Arg 
promote endosome maturation by activating class III PI3K, we will perform a Percoll-
gradient fractionation in cells overexpressing constitutively active class III PI3K. We 
predict expression of constitutively active class III PI3K will rescue the block in 
endosome maturation we observe with c-Abl/Arg inhibition, indicating that class III PI3K 
activation is required for c-Abl/Arg to promote endosome maturation.  
If experiments reveal c-Abl and Arg do not regulate class III PI3K, an alternative 
hypothesis is that c-Abl/Arg phosphorylate the actin nucleation promoting factor, WASH, 
thus promoting actin reorganization, which also is essential for endosome maturation 
[36]. To test this hypothesis, we will perform western blot analysis and observe the 
tyrosine phosphorylation levels of immunoprecipitated WASH in cells with c-Abl/Arg 
inhibition or knockdown. If the inhibition or knockdown of c-Abl and Arg reduces WASH 
tyrosine phosphorylation levels, this would indicate c-Abl/Arg promote WASH 
phosphorylation. To confirm that c-Abl/Arg phosphorylation of WASH is necessary for 
endosome maturation, we would identify and mutate the c-Abl/Arg tyrosine 
phosphorylation sites within WASH to glutamates, creating a WASH phosphorylation 
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mimic. We will perform the previously mentioned Percoll-gradient fractionation 
overexpressing the WASH phosphorylation mimic. If the WASH phosphorylation mimic 
rescues the block in endosome maturation we observe with c-Abl/Arg inhibition, this 
would indicate that c-Abl and Arg require the phosphorylation of WASH to promote 
endosome maturation. To confirm these results, we will also mutate the c-Abl/Arg 
tyrosine phosphorylation sites within WASH to phenylalanines, preventing 
phosphorylation of WASH by c-Abl/Arg. In cells with endogenously low c-Abl/Arg activity, 
such as melanoma WM164 and breast cancer MCF-7 cells, we will overexpress 
constitutively active c-Abl/Arg-PP and mutant WASH and perform Percoll-gradient 
fractionation. We anticipate that blocking c-Abl and Arg from phosphorylating WASH will 
prevent the constitutively active c-Abl/Arg from promoting endosome maturation.  
We also reported for the first time that c-Abl and Arg upregulate cathepsin mRNA 
expression in melanoma and breast cancer cell lines in a kinase-independent manner. 
Cathepsins L and B are regulated by the transcription factor STAT3 [141] and our lab 
previously demonstrated that c-Abl/Arg promote STAT3 phosphorylation [61]; therefore, 
it is conceivable that c-Abl/Arg could promote cathepsin L and B mRNA expression 
through activation of STAT3. Additionally, our lab has also previously demonstrated that 
c-Abl/Arg activation of STAT3 occurs via an indirect mechanism [57]. These data led us 
to hypothesize that c-Abl and Arg activate STAT3 by promoting the degradation of the 
STAT3 inhibitor, PIAS, inducing the upregulation of cathepsin L and B mRNA. We will 
perform several experiments to test our hypothesis. First, we will investigate if c-Abl/Arg 
upregulate cathepsin expression via STAT3 activation. We demonstrated that 
knockdown of c-Abl or Arg decreased cathepsin mRNA levels (Chapter 3); therefore, to 
determine if STAT3 activation is required for c-Abl and Arg cathepsin upregulation, we 
will overexpress constitutively active STAT3 to observe if STAT3 activation rescues the 
decrease in cathepsin mRNA we observe in c-Abl/Arg knockdown cells. Next, we will 
investigate if c-Abl and Arg downregulate the expression of the STAT3 inhibitor, PIAS, 
by performing western blot analysis on whole cell lysates from c-Abl/Arg knockdown 
cells. We expect c-Abl/Arg knockdown will upregulate PIAS protein expression. Finally, 
to confirm that PIAS downregulation by c-Abl/Arg induces STAT3 activation and 
upregulation of cathepsin mRNA, we will use PIAS shRNA to create stable PIAS 
knockdown cells. If c-Abl/Arg require the downregulation of PIAS to activate STAT3 and 
upregulate cathepsin expression, silencing of c-Abl and Arg in cells with stable PIAS 
knockdown will maintain activated STAT3 and cathepsin expression levels as compared 
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to cells expressing endogenous PIAS. However, c-Abl and Arg may be regulating 
cathepsin mRNA expression levels by mechanisms other than transcriptional regulation 
such as promoting mRNA stability by inhibiting deadenylation of the poly (A) tail [154].  
Projects in Progress 
As previously mentioned, in cancer, upregulated cathepsins are often secreted 
into the extracellular environment [38]; therefore, our discovery that c-Abl and Arg 
dramatically upregulate cathepsin expression led us to speculate whether c-Abl and Arg 
may have a role in procathepsin secretion. As described in Chapter 1, procathepsins are 
trafficked through the endoplasmic reticulum to the golgi apparatus [37]. In the golgi, 
cathepsins are targeted to early endosomes which subsequently mature to late 
endosomes [37]. Once in late endosomes, procathepsins are cleaved to their single 
chain active form and trafficked to acidic lysosomes where the cathepsins are cleaved 
again to the double chain active form [37]. In cancer cells, overexpressed procathepsins 
are secreted from the cell rather than the being trafficked to the endosome/lysosome 
pathway [38].  Procathepsins follow the conventional pathway of secretion in which 
proteins localized within the golgi are trafficked via vesicles budding from the golgi to the 
plasma membrane to be secreted (Figure 4.1a) [155]. To examine if c-Abl and Arg 
promote cathepsin secretion, we silenced c-Abl and Arg in BT-549 cells and blotted the 
conditioned media with antibodies to cathepsins known to have a role in invasion and 
metastasis: procathepsin L, B and D [37]. Interestingly, both c-Abl and Arg promote the 
secretion of cathepsins L and D. c-Abl had a more dramatic effect on cathepsin L 
secretion as compared to Arg and cathepsin B secretion was only c-Abl-dependent 
(Figure 4.2 left, middle). These results confirm that c-Abl and Arg mediate procathepsin 
secretion.  
Given that secretion of cathepsins is linked to their increased expression [38, 
156], we examined if cathepsin secretion induced by c-Abl and Arg was due to increased 
cathepsin transcript levels in nutrient-deprived conditions. Using quantitative real-time 
RT-PCR, we observed reduced cathepsin L and D mRNA levels following silencing of c-
Abl or Arg; however, decreased levels of cathepsin B mRNA were observed following 
silencing of c-Abl but not Arg, indicating that cathepsin B mRNA upregulation is c-Abl-
dependent (Figure 4.2 right). Although the changes in cathepsin expression that we 
observe with c-Abl and Arg knockdown are similar between the mRNA and conditioned 
media expression levels, we observed a more dramatic effect on procathepsin 
expression levels in the lysate and media as compared to the mRNA (Figure 4.2). These
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Figure 4.1 Conventional and Unconventional Pathways of Secretion 
a"
b"
c"
d"
 
Figure 4.1 Conventional and unconventional pathways of secretion. (a) 
Conventional Secretion of proteins localized within the golgi are trafficked via vesicles 
budding from the golgi to the plasma membrane to be secreted into the extracellular 
environment (b-d) Unconventional secretion pathways. (b) Secretory lysosomes are 
modified lysosomes that can function in secretion by fusing with the plasma membrane 
and releasing their contents into the extracellular environment. (c) Multivesicular bodies 
are intermediate vesicles that form as late endosomes mature into lysosomes.  
Multivesicular bodies contain endosomal membrane invaginations known as intraluminal 
vesicles (ILVs) that encapsulate proteins. Multivesicular bodies can fuse with the plasma 
membrane and release the ILVs into the extracellular environment as exosomes. (d) A 
phagophore (pre-autophagosome) engulfs and encapsulates a cytoplasmic protein 
forming an immature autophagosome. The immature autophagosome fuses with early 
endosomes, late endosomes, or multivesicular bodies to form an amphisome vesicle. 
The amphisome can then fuse with the plasma membrane to release its contents into 
the extracellular environment. Figure adapted from Zhang, et al. Science. 2013 May 
3;340(6132):559-61.
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Figure 4.2 c-Abl and Arg Increase Cathepsins L, B, and D Expression in Whole 
Cell Lysate, Conditioned Media and mRNA   
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Figure 4.2 c-Abl and Arg increase Cathepsins L, B, and D expression in whole cell 
lysate, conditioned media and mRNA.  (a-c) BT-549 cells were transfected with c-Abl 
or Arg siRNA in 60mm dishes and serum starved for 24 hours. (a-c, left) Cells were 
lysed and blotted with antibodies to procathepsins L (a) , B (b) , or D (c). (a-c, middle) 
Conditioned media (2mL) was collected and filtered through .2 µm filter to remove 
floating cells. Media was concentrated with Millipore Amicon .5mL filter to 200µL. 
Sample buffer (4x) was added to media and boiled for 5’. Equal protein concentrations 
(determined by whole cell lysate protein concentration) were loaded onto a SDS-page 
gel and blotted for prcathepsin L (a) , B (b), or D (c). (a-c, right) Quantitative real-time 
RT-PCR was performed with primers for procathepsin L (a), B (b), D (c) and RPS13 as a 
loading control. (a-c) Graphs represent mean±SEM for 3 independent experiments. 
*p<0.05, **p<0.01, ***p<0.001 using one sample t-tests. 
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data suggest that in addition to increasing transcript levels, c-Abl and Arg also may 
promote procathepsin expression/secretion via an additional mechanism.  
In addition to increased transcript levels, increased expression of procathepsin L 
and B could be due to the presence of multiple transcript variants [156]. Both cathepsins 
L and B have 5 transcript variants all yielding the same protein product due to the 
translation initiation site being located in exon 2 and alternative splicing occurring within 
exon 1 [156]. Interestingly, the shortest transcript is translated more efficiently as 
compared to the longer transcripts due to the shortest transcript containing fewer stem-
loop structures within the mRNA [156]. Furthermore, in comparison to the other 
transcript variants, the shortest transcript has a higher expression level in malignant cells 
[156]. Therefore, in addition to regulating the overall expression of cathepsin L and B 
mRNA, it would be interesting to determine if c-Abl and Arg promote alternative splicing 
of cathepsins L and B, producing the shortest transcript variant and thus, increasing the 
translation efficiency and expression of the cathepsins. Consistent with this hypothesis,  
the constitutively active Abl kinase, BCR-Abl, upregulates expression of multiple genes 
involved in pre-mRNA splicing in hematopoietic cells [157]. Furthermore, inhibition of 
BCR-Abl resulted in splicing patterns consistent with normal cells as compared to 
malignant hematopoietic cells [157]. In solid tumors, such as melanoma and breast 
cancer, we propose c-Abl and Arg may promote the pre-mRNA splicing of cathepsins L 
and B yielding the shortest transcript variant, subsequently increasing translation 
efficiency and procathepsin expression/secretion. Since alternative splicing of 
cathepsins occurs within exon 1, we will test this hypothesis by designing primers to 
span the alternative splicing sites within exon 1 and perform semi-quantitative RT-PCR 
to observe expression changes of the five cathepsin L and B transcript variants with c-
Abl and Arg knockdown.  An alternative hypothesis to consider which also may account 
for the more dramatic effect we observe on secretion as compared to the mRNA levels 
could be that c-Abl and Arg increase the trafficking of vesicles involved in secreting 
cathepsins from the cell. As previously mentioned, procathepsins are trafficked to the 
plasma membrane via vesicles budding from the golgi [155]. A block in golgi vesicular 
trafficking induced by Brefeldin A causes extensive golgi tubulation [158]; therefore, if c-
Abl and Arg promote golgi vesicular trafficking to the plasma membrane, we anticipate 
that silencing c-Abl and Arg will induce golgi tubulation, which can be visualized by 
fluorescent staining with antibodies against the golgi marker, mannosidase A, or by 
electron microscopy. Interestingly, activation of protein kinase D (PKD) is essential for 
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the fission of golgi vesicles destined for the plasma membrane [159] and PKD is a 
substrate of c-Abl [160]; therefore, we hypothesize that c-Abl and Arg promote cathepsin 
secretion by activating PKD, and thus, inducing vesicle budding from the golgi to the 
plasma membrane. If c-Abl and Arg activate PKD to promote trafficking of cathepsins 
from the golgi to the cell surface, we anticipate that overexpression of constitutively 
active PKD will rescue the decrease in cathepsin secretion we observe in c-Abl and Arg 
knockdown cells. 
NM23-H1 has been observed in the extracellular environment; therefore, our 
findings that c-Abl and Arg regulate NM23-H1 expression led us to investigate a role for 
c-Abl and Arg in regulating NM23-H1 secretion. Surprisingly, c-Abl and Arg knockdown 
dramatically decreased NM23-H1 expression in the conditioned media of 435s cells 
(Figure 4.3), indicating that c-Abl and Arg promote the secretion of NM23-H1. 
Interestingly, c-Abl and Arg increase the extracellular expression of NM23-H1 while 
downregulating intracellular levels. These data contrast with c-Abl- and Arg-mediated 
upregulation of cathepsins in which expression is increased both extracellularly and 
intracellularly. Furthermore, c-Abl and Arg increase cathepsin transcript levels, whereas 
c-Abl and Arg do not affect the transcript levels of NM23-H1 (Chapter 3); therefore, c-Abl 
and Arg promote NM23-H1 secretion in a transcription-independent manner. c-Abl and 
Arg-dependent secretion of NM23-H1 may be an additional mechanism by which c-Abl 
and Arg decrease intracellular protein levels of NM23-H1, in addition to lysosomal 
degradation. NM23-H1 lacks the signal-peptide required for conventional secretion [155, 
161]; therefore, c-Abl and Arg are likely promoting NM23-H1 secretion via 
unconventional secretion. Indeed, in Chapter 3, we demonstrated that c-Abl and Arg 
regulate intracellular trafficking of NM23-H1 within endosomes and lysosomes, vesicles 
associated with unconventional secretion. 
Unconventional secretion is defined as secretion which involves mechanisms 
other than vesicles budding from the golgi apparatus [155]. There are several 
mechanisms by which proteins undergo unconventional secretion. These mechanisms 
involve secretory lysosomes, secretion of multivesicular bodies [155], and 
autophagosome-induced secretion [162]. Secretory lysosomes are modified lysosomes 
that can function in secretion by fusing with the plasma membrane and releasing their 
contents into the extracellular environment (Figure 4.1b) [163]. This is an unlikely 
mechanism for NM23-H1 secretion because secretory lysosomes are reportedly only 
found in hematopoietic cells and melanocytes [163]. Although we observe NM23-H1
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Figure 4.3 c-Abl and Arg Increase Expression of NM23-H1 in Conditioned Media  
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Figure 4.3 c-Abl and Arg increase expression of NM23-H1 in conditioned media.  
435s cells were transfected with c-Abl or Arg siRNA in 60mm dishes and serum starved 
for 24 hours. Cells were lysed and blotted for NM23-H1, left. Conditioned media (2mL) 
was collected and filtered through .2 µm filter to remove floating cells. Media was 
concentrated with Millipore Amicon .5mL filter to 200µL. Sample buffer (4x) was added 
to media and boiled for 5’. Equal protein concentrations (determined by whole cell lysate 
protein concentration) were loaded onto a SDS-page gel and blotted for NM23-H1, right. 
Graphs represent mean±SEM for 3 independent experiments. *p<0.05, ***p<0.001 using 
one-sample t-tests. Media prepared by S. Ganguly. 
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secretion in melanomas, the melanocyte secretory lysosomes are described as 
melanosomes which function to secrete melanin [163]; therefore, these would be unlikely 
to contain NM23-H1. Multivesicular bodies are intermediate vesicles that form as late 
endosomes mature into lysosomes.  Multivesicular bodies contain endosomal 
membrane invaginations known as intraluminal vesicles (ILVs) that encapsulate proteins 
[37].  Multivesicular bodies can fuse with the plasma membrane and release the ILVs 
into the extracellular environment as exosomes (Figure 4.1c) [155]. As previously 
mentioned, we demonstrated that c-Abl/Arg promote the trafficking of late endosomes to 
lysosomes and NM23-H1 is localized within these vesicles (Chapter 3); therefore, it is 
possible that c-Abl and Arg may promote NM23-H1 secretion via trafficking of 
multivesicular bodies to the plasma membrane. Autophagosomes can also be involved 
in unconventional protein secretion [164]. Within the cytoplasm, a phagophore (pre-
autophagosome) can engulf and encapsulate a cytoplasmic protein forming an immature 
autophagosome [164]. During autophagy, this autophagosome fuses with lysosomes 
introducing the engulfed proteins to the lysosomal compartment to be degraded [164]. 
Alternatively, this immature autophagosome can also fuse with early endosomes, 
recycling endosomes, late endosomes, or multivesicular bodies to form an amphisome 
vesicle [164-166]. The amphisome can then fuse with the plasma membrane to release 
its contents into the extracellular environment (Figure 4.1d) [164]. Thus, it would be 
interesting to evaluate if, in addition to endosomes and lysosomes, NM23-H1 also 
localizes within autophagosomes. To test this hypothesis, we will perform 
immunocytochemistry and subcellular fractionation to observe if NM23-H1 and the 
autophagosome marker LC3 colocalize. Furthermore, to examine if autophagosome 
maturation is required for NM23-H1 secretion, we can inhibit autophagosome maturation 
by treatment with bafilomycin A, or silencing ATG5, an E3 ligase essential for 
autophagosome maturation, and observe if extracellular levels of NM23-H1 are reduced. 
If we confirm NM23-H1 is being secreted via autophagosome induced unconventional 
secretion, we hypothesize that c-Abl and Arg promote NM23-H1 secretion by promoting 
autophagosome maturation. Consistent with this hypothesis, c-Abl and Arg have been 
shown to promote autophagosome trafficking and autophagosome-lysosomal fusion 
[65]. Additionally, c-Abl and Arg phosphorylate the autophagosomal SNARE, syntaxin 
17, which is involved in the fusion of autophagosomes with other vesicles [167-169]; 
further supporting a role for c-Abl and Arg in promoting NM23-H1 secretion via 
autophagosome trafficking. Interestingly, NM23-H1 uptake by pre-autophagosomes and 
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delivery to the endosomal compartment could not only explain c-Abl and Arg promoting 
NM23-H1 secretion but may also explain the mechanism by which c-Abl and Arg 
promote delivery of NM23-H1 to the endosome for subsequent degradation within the 
lysosome.  
It is well documented that increased cathepsin expression in the extracellular 
environment is an indicator of increased metastasis and poor survival. As previously 
mentioned, activated cathepsins in the extracellular environment increase invasion and 
metastasis by activating proteases such as uPA and MMPs that degrade the ECM [37]. 
Furthermore, cathepsins can also directly degrade the ECM [37]. Inactive procathepsins 
may also promote invasion in the extracellular environment by binding to cell surface 
receptors. In fact, procathepsin D promotes fibroblast outgrowth by binding to the LRP1 
receptor on the cell surface [170]. Additionally, procathepsin B binds to the annexin II 
receptor on the cell surface of breast cancer and glioma cells [171]. Annexin II has been 
demonstrated to promote exocytosis [172, 173]; therefore, it would be interesting to 
examine if c-Abl and Arg promote NM23-H1 secretion via inducing procathepsin B 
exocytosis/binding to annexin II on the cell surface. Consistent with this hypothesis, 
cathepsin B has been shown to promote the unconventional secretion of IL-1β in 
macrophages [174]. To test if extracellular cathepsin B increases NM23-H1 secretion in 
melanoma cells, we will silence cathepsin B and observe if there is a decrease in 
extracellular NM23-H1 levels. To confirm that cathepsin B-mediated NM23-H1 secretion 
is specific to extracellular procathepsin B, we will add procathepsin B to the media in 
cathepsin B knockdown cells and examine if extracellular NM23-H1 expression is 
rescued with extracellular cathepsin B expression. Finally, to investigate if extracellular 
procathepsin B requires annexin II to promote NM23-H1 secretion, we will silence 
annexin II in cathepsin B knockdown cells and observe if adding procathepsin B to the 
media fails to rescue extracellular NM23-H1 levels in annexin II knockdown cells as 
compared to cells expressing endogenous annexin II.  
Interestingly, even though intracellular NM23-H1 has metastasis suppressing 
functions, some data indicate that extracellular NM23-H1 may promote tumor growth, 
angiogenesis, and its secretion has been linked with poor survival in breast cancer and 
hematological malignancies [161, 175, 176]. Given that extracellular NM23-H1 promotes 
proliferation in hematopoietic cells and our lab demonstrated that c-Abl and Arg promote 
proliferation [57] and NM23-H1 secretion in melanoma cells, we hypothesize that c-
Abl/Arg promote proliferation in melanoma cells by increasing NM23-H1 secretion. To 
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test this hypothesis, we will perform a 3H-thymidine proliferation assay and observe if 
recombinant NM23-H1 added to the media of c-Abl and Arg knockdown cells rescues 
the inhibition of proliferation we observe following silencing c-Abl and Arg in melanoma 
cells. To investigate if extracellular NM23-H1 levels may contribute to the decreased 
survival in melanoma patients, we will perform an ELISA to examine if there is a positive 
correlation between NM23-H1 levels in serum from melanoma patients and overall 
patient survival. The results of these experiments may provide evidence for the use of 
NM23-H1 serum levels as a biomarker for melanoma prognosis.  
Clinical Significance 
Melanoma can be categorized into many subtypes, each with their own 
challenges in treatment due to complex signaling pathways promoting tumor progression 
and metastasis. Melanoma prognostic techniques include staging and identifying the 
presence of molecular biomarkers [177]. Although staging indicates how invasive and 
advanced the tumor may be, the complexity and uniqueness of each individual tumor 
requires additional information for accurate diagnosis and treatment options. Metastatic 
malignant melanomas are diagnosed using several biomarkers such as S100, MelanA, 
tyrosinase, and MITF [178]. Once malignant melanoma is diagnosed, identification of the 
tumor molecular profile driving the disease provides clinicians with information to provide 
tailored treatment options for patients. For example, the presence of the V600E BRAF 
mutation is a biomarker for the use of a BRAF inhibitor for melanoma treatment; 
however, not all tumors respond to treatment due to intrinsic or acquired resistance [8]. 
Resistance to BRAF inhibitors does not occur due to secondary mutations within BRAF, 
but instead via upregulation of other pathways, which activate the CRAF isoform [9, 10, 
87]. Although many mechanisms of resistance to BRAF inhibitors have been identified, 
overall survival rates of patients the metastatic melanoma have failed to improve [14]. 
Further investigation and understanding of mechanisms and biomarkers of resistance 
could provide better treatment options for patients. Our lab has previously shown that c-
Abl/Arg promote melanoma progression, [57, 61] and the c-Abl/Arg phosphorylated 
substrates, Crk/CrkL, are intensely stained in melanoma tumors as compared to benign 
nevi (Chapter 2). Furthermore, we examined pCrk/CrkL staining in melanoma subtypes 
and found intense pCrk/CrkL staining in tumors from young patients and with intermittent 
sun-exposure, which commonly present with BRAF activating mutations [1], indicating 
that BRAF mutations may be linked to c-Abl/Arg activity. Interestingly, long-term 
inhibition of BRAF is associated with increased IGFR1 activation and PDGFRα 
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upregulation [179, 180]. IGFR1 and PDGFR are both upstream regulators of c-Abl [47, 
61]; therefore, tumors resistant to BRAF inhibitors may require the activation of c-Abl 
and Arg. These data provoked us to ask the following questions: Is intense pCrk/CrkL 
staining a biomarker for melanoma progression and survival? Are BRAF and c-Abl/Arg 
activity linked in primary melanomas? If so, is the activation of c-Abl and Arg a predictor 
of tumors harboring acquired/intrinsic BRAF resistance?  
Correlating pCrk/CrkL staining with patient survival in a large sample of 
melanoma tumors would provide further evidence for the use of pCrk/CrkL as a 
biomarker for melanoma progression. Furthermore, staining serial sections of tumors 
with pCrk/CrkL and BRAF V600E antibody would address the question whether there is 
a connection between BRAF mutations and c-Abl/Arg activation in primary melanoma 
tumors. Analysis of pCrk/CrkL staining (c-Abl/Arg activity) within tumors resistant to 
treatment with BRAF inhibitors may indicate a link between c-Abl/Arg activity and BRAF 
inhibitor resistance. If tumors staining intensely for pCrk/CrkL are less responsive to 
treatment as compared to tumors with low pCrk/CrkL staining, this suggests that c-
Abl/Arg kinase activation may contribute to intrinsic tumor resistance to BRAF inhibitors. 
However, if tumors resistant to BRAF inhibitors present with increased post-treatment 
pCrk/CrkL staining as compared to pre-treatment staining, c-Abl/Arg activation may 
contribute to acquired resistance to BRAF inhibitors. If there is a correlation between 
pCrk/CrkL staining and BRAF mutation and/or resistance to BRAF inhibitors, we will then 
use a melanoma cell line resistant to BRAF inhibitors to determine if the c-Abl and Arg 
inhibitor, nilotinib, sensitizes cells to the BRAF inhibitor. If we find that c-Abl/Arg 
contribute to BRAF resistance, this would be of particular significance clinically, as 
combination treatment with c-Abl/Arg inhibitors and BRAF inhibitors could likely improve 
treatment response rates and survival.  
Similar to melanoma, breast cancer tumor progression can be assessed by 
stage, grade, and molecular biomarkers. Breast cancer tumors are categorized based on 
the presence/absence of receptors: ER/PR+, HER2+, or triple-negative lacking all three 
receptors [15]. The presence of ER, PR or HER2 receptors provides targeted treatment 
options against the receptor present. In addition to their aggressive phenotype, triple-
negative tumors have limited therapeutic options due to the lack of targetable receptors, 
and thus, have a poor prognosis and decreased rates of survival [17].  Staining of breast 
cancer tumor tissue revealed intense pCrk/CrkL staining in triple-negative tumors and a 
significant positive correlation between pCrk/CrkL staining and high-grade tumors 
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suggests that pCrk/CrkL staining (c-Abl/Arg activity) could be a potential biomarker for 
advanced, aggressive, triple-negative tumors. To test the reliability of pCrk/CrkL as a 
biomarker for breast cancer progression, we will determine if a positive correlation exists 
between pCrk/CrkL staining and patient survival in breast cancer tumor samples. 
Furthermore, high pCrk/CrkL staining in triple-negative tumors as compared to 
ER/PR/HER2+ tumors suggests c-Abl/Arg may be a targetable protein for treatment in 
this aggressive tumor type. To test if inhibition of c-Abl/Arg activity is a viable treatment 
option for patients with triple-negative tumors, we will perform in vivo metastasis 
experiments using human triple-negative breast cancer cell lines with high c-Abl/Arg 
kinase activity and allow tumors to form in the mammary fat pad.  Following the 
formation of lung metastases we will administer nilotinib and observe if metastatic 
burden in nilotinib-treated mice is diminished as compared to vehicle-treated mice. 
Reduced metastatic burden in mice with c-Abl/Arg inhibition would provide convincing 
evidence that c-Abl/Arg could be targeted therapeutically in triple-negative breast 
cancer.  
Taken together, the data presented in this dissertation build upon a body of work 
demonstrating that c-Abl and Arg are potent oncogenes in solid tumors. We present 
novel mechanisms in which c-Abl and Arg downregulate the metastasis suppressor 
NM23-H1, upregulate the pro-tumorigenic proteases, cathepsins L and B, and promote 
the secretion of proteins such as cathepsins L/B/D and NM23-H1. Furthermore, these 
data positively impact both the Abl family kinase and NM23-H1 research fields, and lead 
to a number of new hypotheses, which need to be investigated. Our data strongly 
support the use of FDA-approved c-Abl/Arg inhibitors in the clinic to prevent tumor 
progression and metastasis in tumors with elevated c-Abl/Arg activity.  
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